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The overall aim of the experiments presented in this thesis is to investigate the 
onset and regulation of mRNA splicing in early mammalian development.
To  investigate  splicing  efficiency  in  single  mouse  embryos,  we  have 
constructed splicing probes that exploit the properties of fluorescent proteins. A 
DsRed Express-intron-EGFP construct would report splicing by the expression of 
the fusion DsRed-EGFP protein, when injected in mouse embryos. In the absence 
of splicing the  vector yields  only  DsRed.  The  ability  of the  probe  to  monitor 
splicing was confirmed by compromising the U1  small nuclear ribonucleoprotein 
or by mutation of the nitron’s 5’  splice site. Furthermore, I show that inhibiting 
U1-mediated splicing at the onset of development inhibits development beyond 
the 2-cell stage.
Following the characterization of the splicing probe, the development of 
nuclear  speckles  was  investigated  during  early  mouse  development  by 
determining  the  nuclear  localisation  of  the  splicing  factor  SC35.  These 
experiments  showed  a  developmental  change  in  nuclear  organisation  during 
oocyte maturation  and through embryo development.  We could  also  show that 
splicing takes place as early as the 1-cell stage embryos in the absence of nuclear 
speckles.
Finally, the role of an SR protein, SRp38, was also investigated.  SRp38 
has  been  reported  to  be  a potent  splicing  inhibitor  when  dephosphorylated  in 
mitotic cells or under heat stress. SRp38 was present during all stages of the early 
mouse development. Oocytes and embryos were found to be sensitive to the levels 
of SRp38. Expression of SRp38-EGFP or depletion of SRp38 using morpholinos 
caused an arrest of oocytes at the GV stage and embryos at the 2-cell stage. The
2splicing reporter was used to reveal that these effects were independent of splicing 
suggesting a novel role for SRp38 in cell biology.
These studies provide a novel approach to monitoring splicing activity in 
single living cells and that splicing activity is necessary  for the  onset of early 
mammalian development.
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In  all  eukaryotic  organisms,  gene  expression  requires  splicing.  Splicing  is  a 
process in which short intervening sequences that interrupt the coding sequence in 
a  newly  transcribed  mRNA  are  excised  to  yield  mRNA  with  the  appropriate 
reading  frame  of a  particular  protein.  Splicing  is  an  essential  step  for  gene 
expression  in  higher  eukaryotes  but  it  has  never  been  studied  during  early 
development.
This thesis presents the design of a novel probe for monitoring splicing 
efficiency  using  fluorescent  proteins,  in  single  living  embryos.  Further 
experiments presented in this thesis have been designed to  investigate two  SR 
proteins with opposing properties during the early mouse development.
To  introduce  this  topic  I  will  review  oogenenesis  and  preimplantation 
development,  followed  by  the  mechanisms  involved  in  gene  expression  and 
splicing.
131.1  Early mammalian development
1.1.1  Oocyte development
In mammals the population of oocytes that contribute to fertility are present at the 
time of birth. They are arrested in diplotene of the first meiotic division and are 
surrounded  by  a  single  layer  of  pre-granulosa  cells.  These  are  known  as 
primordial follicles.
In  response  to  an  as  yet  unidentified  signal,  primordial  follicles  are 
stimulated to enter the growing phase. The oocyte increases in diameter from 15- 
20pm to more than  100pm  in  some  species.  In the mouse,  the  oocytes within 
primordial follicles have a diameter of 15pm (~0.9 pi  in volume) and the fully 
grown oocyte,  80pm (-270 pi in volume). As the oocyte grows, the number of 
follicular  granulosa  cells  increases  in  layers  to  form  the  primary  follicle, 
secondary  follicle  and  finally  tertiary  follicle  with  a  large  antral  cavity 
(Chouinard, 1975).
Throughout follicular development the granulosa cells communicate with 
the oocyte via gap junctions (Anderson and Albertini,  1976;Kidder and Mhawi, 
2002). These junctions are composed of connexins, a group of membrane proteins 
that  allow  the  transport  of  small  molecules  (<lkDa)  between  adjacent  cells 
(Herlands  and  Schultz,  1984).  Connexins  are  essential  for  development of the 
oocytes past the preantral stage. This was shown in experiments where connexin 
37  was  knocked  out  in  mice  and  development  of the  follicles  was  arrested 
(Carabatsos  et  al.,  2000).  Furthermore,  communication  via  oocyte  secreted
14factors is also necessary for oocyte development. An example is that of Growth 
Differentiation Factor-9 (GDF-9). Knock-out mice for GDF-9, are infertile due to 
failed ovarian follicular development  (Carabatsos  et al.,  1998).  Finally another 
example of a secreted factor essential for follicular development is that of the kit- 
ligand (Packer et al, 1994).
Concomitant with oocyte growth, a nuclear expansion also occurs.  This 
enlarged nucleus is known as the germinal vesicle (GV).  Changes in chromatin 
configuration also occur during oocyte development. These configurations have 
been termed “surrounded nucleolus” (SN) and “non surrounded nucleolus” (NSN) 
(Bouniol-Baly et al, 1999). In the SN configuration, the condensed chromatin is 
arranged in a rim around the nucleolus of the germinal vesicle. However, in NSN 
the chromatin is not condensed and is distributed throughout the germinal vesicle 
and is not surrounding the nucleolus (Zuccotti et al,  1995). Furthermore, it was 
shown that oocytes progress from the NSN configuration to the SN configuration 
approximately  17 days after birth (Zuccotti et al,  1995). The percentage of SN 
oocytes  was  also  shown  to  increase  with  the  increase  in  oocyte  size. 
Transcriptional activity has also been investigated in these two stages of oocyte 
development. NSN stage oocytes can actively transcribe, while SN stage oocytes 
do not (Bouniol-Baly et al,  1999).  This suggests that in SN stage oocytes, the 
genes required to support early development have been transcribed and stored for 
later translation. Finally, meiotic and developmental competence is significantly 
higher in oocytes that have progressed to the SN configuration at the appropriate
15time,  15-17  days  after birth.  This  suggests  that the  chromatin  configuration  is 
finely tuned with the control of expression and this is essential for further oocyte 
development (Zuccotti et al., 1995;Bouniol-Baly et al., 1999;Liu and Aoki, 2002).
1.1.2  Oocyte maturation
During  oocyte  growth  the  oocyte  remains  arrested  in  the  diplotene  stage  of 
meiosis.  Oocyte  maturation  refers  to  the  progression  from  diplotene  through 
metaphase I to arrest at metaphase  II.  Oocyte maturation is stimulated in fully 
grown oocytes within antral follicles in response to LH (Lunenfeld et al,  1975). 
Maturation can also be stimulated in vitro by releasing the oocyte from the follicle 
into  suitable  culture  media  (Edwards  et  al,  1969).  Oocytes  gradually  acquire 
competence to  resume  meiosis.  Firstly,  oocytes  are  able to  undergo  GVBD  at 
60pm  and  the  ability  to  progress  to  Mil  is  achieved  in  oocytes  of 67pm  in 
diameter (Sorensen and Wassarman, 1976).
After  GVBD,  the  oocyte progresses to  metaphase  I.  The  chromosomes 
become attached to the developing spindle and align on the metaphase plate. The 
spindle is first distinguishable after about 5-6 hours after meiotic resumption and 
is  fully  formed  by  9-10  hours  (Wassarman  and  Albertini,  1994).  The  first 
indication of an animal-vegetal axis occurs at the time the fully formed spindle 
(Zemicka-Goetz,  2002)  migrates  to  the  oocyte  cortex  (Verlhac  et  al.,  2000). 
During  anaphase  I  the  homologous  chromosomes  separate  to  opposite  spindle 
poles. Telophase I completes the cell division marked by the extrusion of the first
16polar  body  (Pbl),  10-12  hours  after the  LH  surge  (Wassarman  and  Albertini, 
1994). Following the completion of Meiosis I, the oocyte enters Meiosis II and 
progresses to form the second meiotic spindle, bypassing the interphase stage. The 
oocyte remains arrested at metaphase of the second meiotic division (Mil) until 
fertilisation takes place.
Regulation of translation plays an important role in oocyte maturation. The 
fate of transcribed mRNA during oocyte growth is tightly controlled and is co­
ordinated  by  a  well  defined  process.  Certain  mRNAs  are  translated  during 
maturation,  whereas  others  are  stored  for  translation  during  later  periods  of 
development.  Regulation  of  translation  is  achieved  by  polyadenylation, 
deadenylation and association of different factors on the mRNA that will regulate 
expression  (Richter  et  al.,  1990).  Early  experiments  showed  that  tissue 
plasminogen  activator  mRNA  (tPA)  was  expressed  during  meiotic  maturation 
following  3’  end polyadenylation (Strickland et al,  1988).  In the  same  study, 
inhibition of translation was achieved by anti-sense RNA complementary to the 3’ 
end of the tPA. The timing of translation is regulated by polyadenylation. mRNAs 
with longer polyadenylated (polyA) tails (-150 residues) are translated, whereas 
mRNAs with shorter polyA tails (<90 residues) may be stored for later translation 
(Bachvarova, 1992). Deadenylation of mRNA can inhibit expression and promote 
storage. Furthermore, masking factors on the mRNAs with shorter polyA tails can 
inhibit  the  binding  of translation  initiation  factors  on  the  capping  machinery, 
therefore  inhibiting  their  expression  (Richter  and  Theurkauf,  2001).  This
17repression  of gene  expression  occurs  during  GVBD.  Expression  of the  stored 
mRNAs is later achieved by the release of the masking factors from the mRNA, 
due  to  their  phosphorylation  by  MPF,  which  leads  to  polyadenylation  and 
expression of the mRNA (Eichenlaub-Ritter and Peschke, 2002).
1.1.3  Fertilisation
Following  sperm  release  into  the  female  reproductive  tract,  it  goes  through  a 
process of competence for fertilisation, called capacitation (Aitken et al.,  1996). 
This process  occurs  during the  transport of the  sperm to  the  ovulated  oocyte. 
Thousands of sperm penetrate the cumulus cell mass which  surrounds the Mil 
arrested  oocyte  and  bind  to  the  zona  pellucida  protein  glycoprotein  ZP3 
(Wassarman et al, 2001). The binding of the sperm to the oocyte’s ZP3, triggers 
the acrosome reaction. In this essential process the acrosome, a secretory vesicle 
in  the  sperm  head,  releases  hydrolytic  enzymes  that  allow  zona  penetration 
(Wassarman et al., 2001). Fertilisation is initiated at the time of sperm fusing to 
the  oocyte’s  plasma  membrane.  The  block  of  further  sperm  penetration  and 
therefore polyspermy is achieved by the event of cortical granule exocytosis that 
results  in  the  release  of hydrolytic  enzymes  from  the  oocyte  to  the  sub-zonal 
(periviteline)  space.  These  enzymes  alter  the  zona  glycoprotein  structure, 
inhibiting further sperm penetration (Wassarman et al., 2001).
Fertilisation results in the resumption of meiosis, releasing the oocyte from 
the Mil arrest, allowing the segregation of the sister chromatids and leading to the
18extrusion of the second polar body (Pb2). The amount of cytoplasm extruded in 
the second polar body is very small, conserving the volume of the early embryo, 
in contrast with the male meiotic process where all four daughter cells receive an 
equal  amount of cytoplasm.  Second polar body  extrusion in the  mouse  occurs 
approximately 90 minutes after sperm-oocyte fusion (Wassarman et al., 2001).
1.1.4  Preimplantation embryonic development
Following  fertilisation,  the  maternal  and  paternal  pronuclei  form  around  four 
hours after the sperm-egg fusion. This stage marks the transition from meiotic to 
mitotic cell divisions. In the mouse, the paternally derived pronucleus develops 
first and  is larger than the female counterpart (Latham, 1999). The pronuclei then 
reposition at the centre of the cell, in such a way that they are positioned closely 
but still remain separate.
The  first  embryonic  division  occurs  17-20  hours  after  fertilisation 
(Howlett and Bolton,  1985;Yanagimachi,  1994). The second embryonic division 
then occurs at 46-54 hours and the embryo reached the 8-cell stage by 60 hours. 
Following the expression of adhesion molecules at the 8-cell stage, the embryonic 
cells,  called  blastomeres,  become  tightly  packed  forming  a  compacted  morula 
(Fleming et al., 2000). This marks the initiation of different embryonic lineages. 
The outer cells will become the trophectoderm and the inner cell mass the embryo 
proper.  These  lineages  are  evident  by  96  hours  after  fertilisation  when  the 
blastocyst  forms.  During  this  period  of  embryo  development,  the  embryo  is
19transported through the oviduct into the uterus.  Finally, the  embryo  will  hatch 
from the  zona pellucida four to  five days after fertilisation and implant  in the 
uterine wall (Timings from Hogan et al., 1994).
1.2  Regulation of gene expression during early development
Gene  expression  during  early  development  is  regulated  by  inactivation  of 
transcription  and  regulation  of translation  thereafter  during  oocyte  maturation 
(section  1.1.2).  Transcription  remains  inactivated  through  the  early  stages  of 
development, until 2-cell stage in mouse, 4-8-cell stage in human, 8-16-cell stage 
in cattle and most domestic species (Kanka, 2003). The stage at which embryos 
become dependent on transcription has typically been demonstrated by sensitivity 
to  an  RNA  Polymerase  II  inhibitor,  such  as  a-amanitin.  For  example,  mouse 
embryos  will  develop  up  to  the  2-cell  stage  in  the  presence  of  a-amanitin. 
Embryos cultured from  1-cell stage in the presence of a-amanitin showed some 
protein synthesis when tested for radiolabeled methionine incorporation. When a- 
amanitin was  introduced  in the medium  at the  early  2-cell  stage,  the  embryos 
arrested, with no methionine incorporation observed.  This finding showed that 
methionine incorporation at the  1-cell  stage was due to  expression of maternal 
transcripts whereas 2-cell stage embryos expressed newly transcribed messages 
(Flach et al, 1982).
Regulation  of gene  expression  is  achieved  in  growing  oocytes  by  the 
inactivation  of transcription  and  later  by  precise  translational  control  of the
20maternal stored mRNAs.  Activation of transcription following fertilisation marks 
the  beginning  of the  zygotic  genome  activation,  a  step  which  is  essential  for 
development.
1.2.1  Embryonic Genome Activation (EGA or ZGA)
Zygotic  genome  activation  is  a  complex process  that  apart  from  activation  of 
transcription  includes  other  nuclear  and  cytoplasmic  events  that  will  ensure 
normal  embryogenesis.  Transcriptional  activation  occurs  in  most  species  in  a 
stepwise manner, called minor and major genome activation.
In the mouse, there is a small burst of transcription in the second half of 
the one-cell stage marking the minor-zygotic genome activation (Latham et al, 
1992;Ram  and  Schultz,  1993).  These  early  experiments  showed  expression  of 
luciferase driven by an SV40 promoter in 1-cell embryos. It was later shown that 
both nuclei contribute to the transcriptional activity of the one-cell stage embryo, 
but the activity of the male pronucleus is 4-5 times greater compared to that of the 
female pronucleus (Aoki et al.,  1997). This was shown in experiments involving 
BrUTP incorporation in the mRNA in the two  pronuclei.  However,  as well  as 
newly  synthesised  transcripts,  maternal  transcripts  are  also  essential  for  the 
transition  to  the  2-cell  stage  (Aoki  et  al,  2003;Zeng  et  al,  2004).  The  first 
proteins  that  have  been  shown  to  be  synthesised  from  maternal  mRNAs  are 
transcription factors (Wang and Latham, 1997;Worrad and Schultz, 1997;Kaneko 
et al, 1997). Microarray studies have recently reported in more detail the groups
21of genes involved in these stages of the ZGA. The main group of proteins which 
are  expressed  in  the  1-cell  embryo  involve  protein  metabolism  and 
phosphorylation,  cell  cycle,  transcription  and  DNA  metabolism  (Zeng  et  al., 
2004). Even though some of the maternal mRNAs are essential for this early stage 
of development, up to 90% of the oocyte RNAs are degraded by the 2-cell stage 
(Nothias  et  al.,  1995;Zeng  et  al.,  2004;Hamatani  et  al.,  2004b).  It  has  been 
recently shown for the first time that splicing takes place from the one-cell stage 
(Zeng and Schultz, 2005). This was shown by microinjecting a reporter gene into 
the male pronucleus of 1-cell embryos, and identifying the spliced products by 
means of PCR. A similar result is also presented later in this thesis.
The major zygotic genome activation occurs in the mouse at the mid-late 
two-cell  stage  (Latham  et  al.,  1991;Nothias  et  al.,  1996).  The  level  of 
transcription is approximately 60-70% higher compared to that of one-cell stage 
embryos  (Aoki et al., 1997). Microarray analysis reveals that the majority of new 
messages  at the  2-cell  stage  are  involved  in  transcription,  mRNA  processing, 
phosphate metabolism, regulation of cell cycle (Zeng et al., 2004) and pyruvate 
metabolism (Hamatani et al., 2004a).
A third wave of transcription named mid-preimplantation gene activation 
(MGA)  has  been  recently  described  which  involves  the  stages  from  4-cell  to 
blastocyst (Zeng et al, 2004;Hamatani et al., 2004a;Zeng and Schultz, 2005). The 
proteins  expressed  between  the  4-cell  stage  and  the  blastocyst  stage  involve 
metabolism, protein and phospholipid biosynthesis ribosome biogenesis (Zeng et
22al., 2004), glucose metabolism and genes involved in the differentiation of the 
embryo to the inner cell mass and trophectoderm (Hamatani et al., 2004a).
These three distinct periods of transcription reflect the major transitions in 
early development. The changing profile of expressed mRNAs at each of those 
transitions is related to the major functions at each stage.
1.2.2  Regulation of transcription depends on RNA Polymerase II.
The state of the RNA Polymerase II plays an important role in the activation of 
the  zygotic  genome.  In  oocytes  and the  first  few  hours  after  fertilisation,  the 
largest subunit of RNA Polymerase II (RPB1) is localised in the cytoplasm with 
its  carboxy-terminal  domain  (CTD)  hyperphosphorylated.  The  CTD  becomes 
dephosphorylated several hours after fertilisation, at the same time that the first 
transcriptional activity is occurring, and by that time it is localised in the pronuclei 
of the early embryo (Bellier et al., 1997). Furthermore, at the onset of the major- 
zygotic  genome  activation,  the  RPB1  becomes  hyperphosphorylated  by  TFIIH 
kinase. These experiments suggested that the RPB1  could potentially regulate the 
onset of zygotic genome activation (Bellier et al.,  1997). Even though the main 
role of RNA Polymerase II is transcription, it is also implicated in other processes 
which will be discussed later.
Transcription alone is not sufficient to yield the appropriate mRNA coding 
sequence to express functional proteins.  The process of splicing is an essential 
step after transcription and before translation that is necessary for the expression
23of  functional  proteins.  Up-regulation  of  transcripts  for  splicing  and  mRNA 
processing at the major and minor phases of zygotic genome activation suggest 
that this is an important developmentally regulated event.
1.3  The process of Splicing
Most  genes  in higher eukaryotes  contain several  intervening  sequences,  called 
introns that interrupt the coding sequence of the gene. In humans for example, an 
average gene is 27kb long,  with an average of 8.8  exons per gene,  each exon 
having a mean size of 145 nucleotides. This means that there is an average of 7.8 
introns per human gene (Lander et al., 2001). These introns need to be precisely 
excised from the pre-messenger RNA (pre-mRNA) to obtain mature mRNA with 
the  appropriate  coding  sequence.  After  intron  excision,  the  two  flanking 
sequences are ligated together using sequential trans-esterification reactions. This 
splicing process  is  achieved  by  a multi-component  complex  that  is  called  the 
spliceosome. The main components of the spliceosome are five uridine rich small 
nuclear ribonucleoprotein particles (UsnRNPs or snRNPs) as well as a number of 
other splicing factors mainly belonging to the SR protein family (Gall, 2000;Patel 
and  Steitz,  2003;Shin  and  Manley,  2004).  It  has  been  believed  for  years  that 
splicing is a process that takes place only in the nucleus of the cell. A recent study 
in anucleate platelets revealed that splicing can also take part in the cytoplasm 
(Denis et al, 2005).
241.3.1  SnRNP biogenesis
The major spliceosomal snRNPs are Ul, U2, U4, U5 and U6. The biogenesis of 
these  molecules  is  a  complex  process  and  many  aspects  of it  remain  poorly 
understood. The snRNA of these precursors of these proteins with the exception 
of  U6  are  transcribed  by  RNA  Polymerase  II  and  contain  additional  3’ 
nucleotides.  While the  snRNA  is  in the  nucleus  it  acquires  a monomethylated 
m7GpppG cap structure, which is required to facilitate export from the nucleus 
(Hamm  and  Mattaj,  1990).  In  the  cytoplasm,  the  UsnRNA  then  acquires  a 
complex  of seven  Sm  proteins,  B/B’,  D3,  D2,  Dl,  E,  F  and  G  in  a  stepwise 
manner, to form the snRNP Sm core structure (Will and Luhrmann, 2001). The 
SMN complex also plays an essential role in the assembly of the snRNPs (Gubitz 
et al., 2004) due to its capacity to bind to both Sm proteins and snRNAs. The 
SMN complex comprises of the survival of motor neurons protein (SMN) and at 
least six other proteins named Gemins (Gubitz et al, 2004). The m7G cap of the 
snRNA  is  then  converted  to  the  2,2,7-tri-methylated  guanosine  (m3G),  by 
trimethyl guanoside synthase I (Tgslp) (Colau et al., 2004). The last process of 
the  cytoplasmic  maturation of the  snRNA  is that  of removal  of the  extra -20 
nucleotides transcribed on the 3’  end of the snRNA (Neuman, V and Dahlberg, 
1990). The m3G cap is then recognised by Snurportin-1  (Huber et al,  1998) and 
importin-P (Palacios et al., 1997;Huber et al., 1998), two factors that are required 
for the snRNP import. The final maturation processes that occur in the nucleus are 
the pseudouridylation and the 2’-0-methylation,  followed by the association of
25the UsnRNP specific proteins, Ul-A and U2-B\ However, the factors involved in 
these processes are currently unknown (Will and Luhrmann, 2001).
The five snRNPs are synthesised both in the nucleus and the cytoplasm, 
while UsnRNP U6 is synthesised entirely in the nucleus by RNA Polymerase III 
and acquires a different cap structure known as y-monomethyl cap structure. The 
other main difference with the other snRNPs is that in place of the Sm proteins, 
U6  associates  with the  Sm  like proteins,  LSm2,  LSm3,  LSm4,  LSm5,  LSm6 , 
LSm7  and  LSm8 .  The  pseudouridylation  and  the  2’-0-methylation  processes 
remain the same as those discussed earlier (Will and Luhrmann, 2001).
The final stage of maturation of snRNPs occurs in the cajal bodies, also 
known as coiled bodies. In these structures the snRNPs are also temporarily stored 
(Gall, 2000) (also see 1.3.4).
1.3.2  Spliceosome assembly and function (Major-class pathway)
As mentioned earlier, the splicing reaction is performed by the spliceosome. The 
key players of the spliceosome are the five snRNPs and a number of non-snRNP 
proteins, such as SR proteins (see section 1.4). The splicing process is achieved by 
a  series  of RNA-RNA,  RNA-protein and protein-protein  interactions  (Hastings 
and Krainer, 2001b).
The  diagram  below  shows  the  consensus  sequences  of the  major  and 
minor pathway introns and branch points. These are the typical sequences that are 
recognised by the splicing machinery in the  5’splice site, the  3’  splice and the
26branch point. In the diagram below (Figure 1.1), the size of its letter demonstrates 
the percentage occurrence of the nucleotide in the particular position,  i.e.  a full 
size letter represents 100% occurrence in the particular position. The vertical lines 
in the diagram also show the sites where the mRNA is excised.
3' splice site 5' splice site Branch point 
sequence
Minor
Major-
class
5' exon 3' exon
Figure 1.1. The consensus sequences of the 5’ splice site, 3’ splice site and branch point 
involved in both the major as well as the minor class splicing pathway. The size of each 
letter demonstrates the percentage occurrence of the nucleotide in the particular position. 
The 5’  and 3’  splice sites show the excision points on the mRNA. Finally the relative 
position of these three consensus sequences within the intron are also shown. From (Patel 
and Steitz, 2003).
The mature spliceosome is built in a stepwise manner that has been broken down 
to series of complexes. There are four distinct complexes on the way to form the 
mature spliceosome. These complexes are E, A, B (shown in figure 1.2), and C in 
that order. The E complex is formed by the attachment of the U1  snRNP to the 5’ 
splice  site  (Mount  et  al.,  1983;Seraphin  and  Rosbash,  1989).  A  recent  study 
demonstrates that  SF1  that binds to the branch site following the U1  snRNP  5’ 
splice site recognition (Kent et al., 2005), compared to earlier studies implicating 
the  function of SF1  at the A complex (Berglund et al.,  1997).  Furthermore, the
27attachment of the U2  auxiliary  factor (U2AF) to the pre-mRNA occurs  at this 
stage.  The  U2AF  is  a  heterodimer  of U2 AF65  and  U2AF35  that  bind  to  the 
polypyrimidine tract found before the 3’ splice site and 3’ splice site, respectively 
(Ruskin et al, 1988). At the same time another essential splicing factor, UAP56, 
that plays a role later in mRNA export is recruited to the spliceosome in a manner 
dependent on U2AF65 (Fleckner et al,  1997).  In the A complex the U2 snRNP 
(Zhuang  and  Weiner,  1989)  as  well  as  Splicing  Factor  3b  (SF3b)  bind  to  the 
branch  site  (Kramer  and  Utans,  1991).  The  tri-snRNP  of U4/U6oU5  is  then 
recruited to the spliceosome to form the compex B (Konarska and Sharp,  1987), 
with  U4  and  U6   being  extensively  base  paired  (Wolff and  Bindereif,  1993). 
Structural changes in U4 and U6 result in juxtaposition of the 5’  and 3’  splice 
sites, and the release of the U1  and U4 (Lamond et al,  1988). U6 then forms a 
base pair bond with the 5’ splice site (Wassarman and Steitz, 1992) and the 3’ of 
U6  base pairs to the 5’  of U2 (Wu and Manley,  1991).  The cleavage of the 5’ 
exon-intron junction  occurs  due  to  the  nucleophilic  attack  from  a  conserved 
adenosine  residue  at  the  nitron’s  branch  site.  This  step  generates  a  free  3’ 
hydroxyl group and the 5’ exon as well as a branched lariat intermediate(Moore 
and Sharp,  1993).  In the last complex,  C,  U5  base pairs to both the 5’  and 3’ 
splice sites bringing them together. The second step of splicing occurs by the 3’
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29exon being attacked by the 3’ hydroxyl group found in the 5’ exon. At the same 
time the lariat intron is released completing the splicing process (Newman, 1997). 
However, an alternative model of the U5 function has also been proposed. U5 was 
proposed to take part in 5’ splice site selection in collaboration with U1  and the 
conserved  splicing  factor  Psp8  before  the  binding  of U2  to  the  branch  point 
(Wyatt et al, 1992;Maroney et al., 2000). It is currently not yet clear which of the 
two models is correct.
1.3.3  Minor-splicing pathway
The  major  class  pathway  of splicing  described  above  recognises  introns  with 
highly conserved dinucleotides in the intron termini, GT for the 5’  end and the 
AG for the 3’ end. In 1994 however, introns with non-consensus splice sites were 
first discovered (Hall and Padgett, 1994). In the same study it was also shown that 
a distinct spliceosome was responsible for the  splicing of such introns and the 
snRNPs involved in this process were of very low abundance. The 5’ splice sites 
and  3’  splice  sites  that  involved  this  new  pathway  had  termini  AT  and  AC 
respectively. The two newly identified snRNPs were shown to be Ull  and U12 
with properties mimicking those of U1  and U2 described earlier (Montzka and 
Steitz,  1988).  Furthermore,  there  was  no  polypyrimidine  tract upstream the  3’ 
splice site in these introns and therefore there was no factor equivalent to U2AF 
involved in their splicing (Dietrich et al.,  1997).  It was later shown that the U4 
and U6  snRNPs were  substituted  in this  second  spliceosome with U4atac  and
30U6 atac (the atac denotes the different termini) (Tam and Steitz,  1996).  Finally, 
the U5 snRNP serves as a factor involved in both spliceosomes. This suggests that 
U5 does not base pair with sequences that are different in genes spliced by the two 
different spliceosomes. The role of U5 in the minor-class pathway is to form the 
U4atac/U6atac0U5 tri-snRNP (Schneider et al., 2002) (an analogue of U4/U60U5) 
and to recruit other protein factors which are important in this splicing pathway 
(Patel and Steitz, 2003). The occurrence of introns that are spliced by the minor- 
class pathway of splicing varies in animal between  1   in  100 to  1   in 300 genes 
(Patel and Steitz, 2003).
1.3.4  Spatial Organisation of UsnRNPs and other splicing factors
Early immunofluorescence experiments localised UsnRNPs to the nucleus of the 
cell but the studies did not yield any information as to how they were organised in 
the nucleus and in which structures transcription or splicing take place (Lobo et 
al.,  1988).  Later  experiments  where  snRNPs  were  tagged  with  fluorescent 
proteins, yielded more information to how these structures are organised in the 
nucleus. Newly synthesised snRNPs localise firstly to the coiled or Cajal bodies 
(Sleeman and Lamond, 1999). Cajal bodies are nuclear spherical structures of 0.3- 
1 pm diameter that act as storage or maturation sites for transcription and splicing 
factors. However, transcription and splicing do not take place in the Cajal bodies 
(Gall,  2000).  SnRNPs  localise  in  nuclear  “speckles”.  These  are  spherical 
structures between 0.8-1.8pm in diameter consisting of snRNPs, SR proteins (see
31section 1.4 ), other splicing and transcription factors and 3’end maturation proteins 
(Mintz  and  Spector,  2000).  Furthermore,  it  has  been  reported  that 
phosphatidylinositol  phosphate  kinases  and  phosphatidyl  inositol  bisphosphate 
(PIP2)  localise  in  these  structures,  suggesting  that  these  lipids  and  their  lipid 
kinases  may  be  involved  in  regulation  of splicing  (Boronenkov  et  al,  1998). 
These speckle structures are otherwise known as interchromatin granule clusters 
(IGCs). IGCs appear to be important in the assembly and modification of splicing 
factors,  but the  fact that RNA Polymerase  II  does  not co-localise  in the  same 
structure  suggests  that  transcription  and  splicing  do  not  take  place  in  these 
structures (Mintz and  Spector,  2000).  Perichromatin fibrils (PFs)  are  structures 
found  in  close  proximity  to  the  IGCs  and  also  scattered  within  the  nucleus 
(Spector, 2001). These are the areas where transcription and its related processes 
take  place  (see  section  1.3.5)  (Parfenov et al.,  2003).  The  factors  required  for 
these processes are recruited from the neighbouring IGCs.  Upon completion of 
transcription, these factors return to the IGCs. IGCs are important structures for 
transcription and pre-mRNA splicing, and their disassembly dramatically reduces 
mRNA  splicing  and  inhibits  the  coordination  of  transcription  with  splicing 
(Sacco-Bubulya  and  Spector,  2002).  Finally,  it  has  been  shown  that  splicing 
factors  such  as  SC35  and  RNA  Polymerase  II  localise  in  the  cajal  bodies  in 
transcriptionally inert cell types, such as antral follicles (Parfenov et al, 2003).
It has been believed for years that splicing takes part only in the nucleus of 
the cell, as described above. A recent study in anucleate platelets has revealed that
32splicing can also take place in the cytoplasm (Denis et al., 2005). Even though 
these platelets do not possess a nucleus, splicing factors have been shown to exist 
and function in the cytoplasm of the cell.
1.3.5  Integration  of  transcription,  capping,  polyadenylation,  and  nuclear 
export with splicing.
Most  biology  textbooks  still  present  splicing  to  occur  after  transcription  is 
completed. However, splicing has been shown to occur cotranscriptionally and is 
tightly  coupled  to  RNA  polymerase  II  (Bentley,  2005).  It  has  been  recently 
shown that splicing and polyadenylation can be completed by the time that the 
polymerase has transcribed  lkb beyond the processing sites and such a process 
can occur in 30 seconds in vivo. However, in vitro where splicing is uncoupled 
from  transcription  the  process  takes  place  more  slowly  and  may  take  hours 
(Wetterberg et al, 2001).
The  regulation  of transcription  and  the  associated  processes  mentioned 
above  are  controlled by  the  C-terminal  domain  (CTD)  of the  large  subunit  of 
RNA polymerase II, also known as RPB1  or LS. The importance of the CTD is 
shown in experiments where truncation of the  CTD causes defects  in capping, 
polyadenylation and splicing (McCracken et al., 1997;Misteli and Spector, 1999). 
The important sequence in the CTD is a series of Y1S2P3T4S5P6S7 heptad repeats. 
There are 27 tandem heptad repeats in the yeast and 52 in humans. However, the
33in vivo functional unit requires only a pair of these tandem repeats (Stiller and 
Cook, 2004).
Phosphorylation of particular amino acids of the heptad repeats regulates 
the integration of other processes with transcription. After transcription initiation, 
the serine 5 of the CTD heptad repeat is phosphorylated by the TFIIH-associated 
kinase (Cho et al, 2001). This phosphorylation removes the initiation factors from 
the pre-mRNA complex and recruits the capping machinery. Capping protects the 
mRNA  from  degradation  and  occurs  when  the  pre-mRNA  is  only  20-40 
nucleotides  long.  Serine  5  is  subsequently  dephosphorylated  to  release  the 
capping machinery (Komamitsky et al, 2000).
The  elongation  factors  are  then  recruited  by  P-TEFb,  in  a  manner 
dependant  on  phosphorylation  of Serine  2  of the  heptad  repeat  (Maniatis  and 
Reed, 2002). One of these recruited factors is TAT-SF1, which is responsible for 
recruiting the spliceosomal U small nuclear ribonucleoproteins (snRNPs) to the 
nascent mRNA and strongly stimulates transcription elongation as well as splicing 
(Fong  and  Zhou,  2001).  Further  evidence  to  support  the  connection  between 
transcription  elongation  and  splicing  is  that  genes  containing  introns  are 
transcribed more efficiently (McCracken et al, 1997;Fong and Zhou, 2001).
The  3’  end  maturation  of the  newly  transcribed  mRNA  is  also  tightly 
controlled by the CTD phosphorylation status.  Serine 2  phosphorylation of the 
CTD  leads  to  mRNA  maturation  of the  3’  end  including  the  cleavage  of the
34nascent  mRNA  20-30  bases  downstream  of a  conserved  poly  A  site  and  the 
polyadenylation by polyA polymerase (PAP) (Proudfoot, 2004).
Finally, transcription is indicated to be involved with splicing and nuclear 
export  of the  newly  transcribed  and  processed  mRNA.  Even  though  nuclear 
export occurs after 3’ mRNA maturation, it has been indicated that it is coupled to 
splicing. The Transcription/Export (TREX) complex of proteins is constituted by 
the THO complex of proteins, which consists of five proteins (their properties are 
yet to be identified), UAP56 and Aly (Reed and Cheng, 2005). This complex of 
proteins  is  involved  in  the  nuclear  export  of the  mRNA.  The  splicing  factor 
UAP56 described earlier, recruits the mRNA export factor Aly to  the  splicing 
complex  (Zhou  et  al,  2000;Luo  et  al,  2001).  This  is  demonstrated  by 
experiments where UAP56 and Aly co-localise in the spliceosome (Custodio et 
al, 2004). Following the splicing reaction, it is suggested that Aly binds to TAP, a 
protein that is involved in mRNA export by bringing the mRNA to the nuclear 
pore (Strasser and Hurt, 2001). However, the role of the THO part of the TREX 
complex is not yet clear. The fact that components of the THO associate with the 
spliced  but  not  unspliced  mRNA  indicates  its  involvement  in  splicing  and 
furthermore its coupling to transcription (Reed and Cheng, 2005).
351.4  SR proteins and splicing
The SR family proteins are essential splicing factors with multiple splicing roles 
in both major and minor splicing pathways (Hastings and Krainer, 2001a). Their 
main roles  are  splice  site  selection  ,  promotion  of the  spliceosome  assembly 
(Hertel  and  Graveley,  2005)  and  regulation  of alternative  splicing  (Wang  and 
Manley, 1995;Mayeda et al, 1999).
1.4.1  SR protein properties and their involvement in splicing
SR  proteins  are  conserved  throughout  the  metazoa.  Their  N-terminal  domain 
contains either one or two RNA binding domains that interact with the pre-mRNA 
whereas the C-terminal domain is the serine / arginine rich domain that acts as a 
protein interaction domain (RS domain) (Graveley, 2000).
The RNA-binding domain of the SR proteins can bind to the pre-mRNA in 
the absence  of the RS  domain (Caceres and Krainer,  1993;Tacke and  Manley, 
1995). However, deletion of the RS domain prevents binding of the SR protein to 
RNA Polymerase IIRPB1, possibly disturbing the integration of transcription and 
splicing (Misteli and Spector,  1999). The RNA-binding domain has been shown 
to bind to exon sequences and enhance the splicing of the adjacent exon. These 
exon sequences are called exonic  splicing enhancers  (ESEs)  and can be  found 
either upstream of the 5’ splice site or downstream of the 3’ splice site. Following 
the binding of the  RNA binding domain in the  ESE other  splicing factors  are 
recruited to the site of splicing.
36In the  case  of the ESE found downstream  of the  3’  splice  site, the  RS 
domain of the SR protein interacts with U2 AF35 and recruits it to the 3’ splice site. 
U2AF65 and the rest of the spliceosome are then recruited to the splice site. There 
is evidence that such a recruitment of the spliceosome can be facilitated by SC35 
or SF2/ASF in a RS-domain dependant manner (Wu and Maniatis, 1993).
It was  shown in earlier studies that when an ESE is  found upstream the of 5’ 
splice site, the bound SR protein ASF/SF2, interacts with the 70 kDa of the U1 
snRNP and stimulates the binding of the U1  snRNP to the downstream 5’ splice 
site (Wu and Maniatis, 1993). It was later shown that such an interaction does not 
actually occur, but ASF/SF2 cooperates with U1 and enhances the recognition of 
the 5’ splice site (Kohtz et al, 1994;Cao and Garcia-Bianco, 1998). A further role 
of the  SR proteins is to recruit the U4AJ6oU5  tri-snRNP  into the spliceosome 
(Roscigno and Garcia-Bianco, 1995). However, the precise role in this activity is 
not yet known. Two novel SR proteins, U4/U6oU5-27K (Fetzer et al, 1997) and 
U5-100K  (Teigelkamp  et al,  1997)  were  later  identified  on  the  tri-snRNP  as 
candidates for this activity, but an RNA binding domain for these proteins has not 
yet been identified.
Recently,  a completely different model  of the  RS  domain  function  has 
been presented. It is proposed that the ESE-bound SR protein does not bind with 
its RS domain to an UsnRNP or to U2AF as earlier described but to the branch 
site, in a process that  promotes the pre-spliceosome assembly (Shen et al, 2004). 
It was later shown by the same group that prior to pre-spliceosome assembly, the
37RS domain of the U2AF65 binds to the branch site by its RS domain during the 
formation of complex E. Finally, a third SR protein binds by its own RS domain 
to the 5’  splice site to complete assembly of the mature spliceosome (Shen and 
Green, 2004). The group suggests that this model fits with earlier data of 5’ splice 
site selection by ASF/SF2 (Zuo and Manley,  1994) or the promotion of the U1 
5’splice site interaction (Eperon et al,  1993), but such a model has not yet been 
confirmed by other groups.
It was recently shown that SR proteins are also involved in the minor-class 
splicing pathway. In this study by Hastings and Krainer, it was shown that the SR 
proteins are involved in the formation of splicing complex A and therefore are 
involved  in the  assembly  of the  second  spliceosome.  Addition  of recombinant 
9G8 or SRp55 activated splicing of a minor-class pathway intron in the SCN4A 
gene. However, the two main SR proteins SC35 and ASF/SF2 could not activate 
splicing of this gene. However, when an exonic splicing enhancer was introduced 
on the gene, ASF/SF2 but not SC35 was able to activate splicing, presenting a 
novel role of the SR proteins (Hastings and Krainer, 2001a).
1.4.2  Novel Roles of the SR proteins
SR proteins were considered for years to be specifically involved in splicing, but 
recently three novel roles of the SR proteins were demonstrated.
Firstly, they were shown to associate with intronless or spliced mRNAs 
and facilitate their export to the cytoplasm (Huang and Steitz, 2001;Masuyama et
38al,  2004).  However, only proteins  such as  SRp20,  9G8  and ASF/SF2  that are 
shuttling between the nucleus and the cytoplasm (Caceres et al,  1998) can take 
part in this pathway. On the other hand, SC35 that does not shuttle between the 
nucleus  and the  cytoplasm  due  to  a  strong nuclear  retention  signal  on  its  RS 
domain and as such, does not take part in mRNA nuclear export (Cazalla et al, 
2002). The export of the mRNA is facilitated by the recruitment of the general 
export receptor TAP, to the mRNA by the SR protein, which later associates with 
the  Aly  family  or  export  adapter proteins that  export the  mRNA  (Huang  and 
Steitz, 2005).
Secondly, shuttling SR proteins and in particular SF2/ASF was shown to 
be involved in mRNA translation. SF2/ASF associates with translating ribosomes 
and  can  stimulate  translation  even  if  splicing  was  not  earlier  required.  The 
shuttling ability of the protein was also shown to increase when an exonic splicing 
enhancer was present (Sanford et al, 2004). Even though the precise role of the 
SR protein in translation is not yet identified, mRNA synthesis, processing and 
now translation appear to be linked.
Thirdly,  SR  proteins  have  been  shown  to  be  involved  in  mRNA 
surveillance and quality control. Overexpression of SR proteins such as SF2/ASF 
or  SC35  had the  effect of increasing the  targeting  of mRNAs  with premature 
termination codons  to  non-sense  mediated  decay  (NMD)  (Zhang  and  Krainer,
2004),  a process  of degradation of mRNAs  containing  stop  codons  in regions
39close  to  -25  nucleotides  upstream  of a  splicing  generated  exon  (Lejeune  and 
Maquat, 2005).
1.4.3  Regulation of SR proteins
SR protein localisation and function are regulated by phosphorylation both for 
their  splicing  and  nuclear  shuttling  activity.  SR  proteins  are  active  when 
phosphorylated in their serine residues and are recruited from the nuclear speckles 
to the spliceosome for the splicing reaction to take place (Misteli et al., 1998;Xiao 
and Manley,  1998).  During splicing, they become partly dephosphorylated and 
return  to  the  speckles  where  another  round  of phosphorylation  and  activation 
takes place (Misteli et al., 1998). Dephosphorylation of SF2/ASF was shown not 
only to repress splicing, but its dephosphorylation was shown to be essential for 
the  first trans-esterification reaction of splicing (Cao et al.,  1997).  In contrast, 
dephosphorylation  of other  SR  proteins  such  as  SRp38  was  shown  to  inhibit 
splicing  in  HeLa  cells  (Shin  and  Manley,  2002).  At  the  same  time, 
dephosphorylation is  important in  shuttling proteins  such as ASF/SF2,  9G8  or 
SRp20,  in order to  shuttle  from  the  nucleus  to  the  cytoplasm  (Caceres  et al., 
1998;Huang et al., 2004).
However,  SR proteins with a strong nuclear retention  signal,  such as  SC35  or 
SRp40,  do  not  shuttle between the nucleus  and  the  cytoplasm  (Caceres  et al., 
1998). The difference between shuttling and non-shuttling proteins lies in the RS 
domain of these proteins (Caceres et al.,  1998;Cazalla et al., 2002). The strong
40nuclear retention signal on SC35 was shown to be in a 30 amino acid proline rich 
segment at the C-terminus of its RS domain. In the same study it was shown that 
10 consecutive RS dipeptides on SF2/ASF are enough for normal localisation and 
splicing activity of the SR proteins, compared to the wild type form of the protein, 
where the same number of dipeptides is scattered through 31  more amino acids 
(Cazalla et al, 2002).  After shuttling to the cytoplasm in the dephosphorylated 
form, phosphorylation is required for nuclear import (Lai et al, 2000).
SR protein phosphorylation and localisation are  also  important  in early 
development.  In  the  early  nematode  embryo,  SR  proteins  are  found  in  the 
cytoplasm  in  their  hyperphosphorylated  form.  Following  zygotic  genome 
activation,  the  proteins  become  partially  dephosphorylated,  to  reach  an 
intermediate  stage  of phosphorylation  and  localise  in  the  nucleus  of the  cell 
(Sanford and Bruzik, 1999;Sanford and Bruzik, 2001).
There are three different protein families that can phosphorylate the  RS 
domains of SR proteins.  These are the  SR protein kinase family (SRPK  1   and 
SRPK2), Clk/Sty family and the DN A topoisomerase I. SF2/ASF was shown to be 
phosphorylated by SRPK1  and SRPK2. The two kinases were both localised in 
the nucleus and the cytoplasm,  suggesting the  role  of phosphorylation both  in 
activation  of  splicing  within  the  nucleus  and  the  role  of  cytoplasmic 
phosphorylation for return of the shuttling SR proteins back to the nucleus (Wang 
et al, 1998;Koizumi et al, 1999;Aubol et al, 2003).  The Clk/Sty kinase was also 
shown to phosphorylate SR proteins, but it only localises in the nucleus of the
41cell.  Furthermore,  hypo-phosphorylation  or  hyper-phosphorylation  of  the  SR 
proteins by the Clk/Sty can cause inhibition of splicing and also alternative splice 
site  selection  (Prasad  et  al.,  1999;Prasad  and  Manley,  2003).  Finally,  DNA 
topoisomerase I can also phosphorylate SR proteins and potentially regulate pre- 
mRNA splicing. DNA topoisomerase depletion experiments demonstrated hypo- 
phosphorylation of the SR proteins and alternative splice sites being selected due 
to impairment of the exonic splicing enhancer splicing (Rossi et al., 1996;Soret et 
al.,  2003).  The  only  phosphatase  believed  to  be  involved  in  at  least  one 
dephosphorylation  event  during  spliceosome  assembly  is  PP2cy.  The  precise 
mechanism of its role still remains to be investigated (Murray et al., 1999).
1.5  Alternative splicing
Alternative splicing is an important mechanism that contributes significantly to 
the  regulation  of  gene  expression.  Alternative  splicing  can  regulate  protein 
function  by  inclusion  or  exclusion  of  a  particular  domain  in  the  mRNA. 
Furthermore, it can regulate gene expression by producing spliced transcripts that 
are susceptible to mRNA degradation (Lareau et al., 2004). A recent study that 
analysed 10,000 human genes shows that at least 74% of the investigated genes 
were alternatively spliced (Johnson et al., 2003).
421.5.1  Types of alternative splicing
There are five different types of alternative splicing. The most common one with a 
38% of occurrence in the alternative splicing events  is the  exon skipping.  The 
second most common alternative splice events are those of alternative  5’  or 3’ 
splice  site  selection  with  occurrence  18%  and  8 %  respectively  over  the  total 
amount  of alternative  splice  site  events.  Intron  retention  accounts  for  3%  of 
alternative  splicing  events.  Finally,  the  remaining  occurrence  includes  more 
complex  events  that  consist  of  mutually  exclusive  events,  multiple 
polyadenylation sites and alternative transcription sites (Ast, 2004).
1.5.2  Regulation of Alternative Splicing
Alternative splicing can be regulated by four distinct elements that are found in 
the mRNA.  These  include Exonic  Splicing Enhancers (ESEs),  Exonic  Splicing 
Silencers  (ESSs),  Intronic  Splicing  Enhancers  (ISEs)  and  Intronic  Splicing 
Silencers (ISSs) (Garcia-Bianco et al., 2004).
ESEs are sequences that are recognised by SR proteins. Upon binding of 
the SR protein to the ESE, the splicing machinery is recruited for splicing to take 
place.  Examples  of  SR  proteins  that  possess  such  properties  are  SF2/ASF 
(Bourgeois et al., 1999) or SC35 (Liu et al., 2000). Finally,  more than 50% of the 
mutations  involved  in exon  skipping are  due to  mutations  found  in ESEs that 
affect the target motifs of SR proteins (Liu et al., 2001).
43ESSs however repress the splicing of a particular exon. This repression is 
facilitated by specific proteins of the hnRNP family. These proteins bind to the 
ESSs  and  compete  with  U2AF65  for  binding  to  the  polypyrimidine  tract,  and 
therefore  inhibit  the  assembly  of the  spliceosome  (Domsic  et  al.,  2003).  An 
example of such a protein is hnRNP Al which has been also shown to antagonise 
other SR proteins for exon definition (Caceres et al, 1994;Eperon et al, 2000). In 
overexpression studies,  SF2/ASF overexpression favours the proximal  5’  splice 
site, whereas overexpression of hnRNP Al favours the distal 5’ splice site (Zhu et 
al, 2 0 0 1 ).
Intronic enhancer sequences have been shown to enhance splicing of the 
5’  splice  site  found  in the vicinity  of the  enhancer  sequence.  The  first  one  is 
UGCAUG,  which  is  found  predominantly  in  the  brain  or  neural  tissues 
(Minovitsky  et  al,  2005).  The  selection  of this  intron  enhancer  sequence  is 
mediated by Fox-1, but the mechanism by which splicing is mediated is not yet 
known (Nakahata and Kawamoto, 2005). Another intronic enhancer sequence is 
that  of GGG  which  is  suggested  to  recruit  U1  snRNP  to  the  5’  splice  site 
(McCullough  and  Berget,  2000).  A  protein  that  also  has  be  involved  in  the 
recognition of intronic splicing enhancers is hnRNP K, but its involvement with 
the spliceosome assembly is yet to be identified (Expert-Bezancon et al, 2002). 
Nova-1  is finally another example of a protein involved in regulation of splicing 
by  recognising  UCAU  repeats  mainly  in  neuronal  tissues  (Buckanovich  and 
Darnell, 1997).
44Finally, intronic splicing silencers inhibit splicing of the particular intron 
and have an effect on alternative splicing. The size of these sequences varies but 
they are found in close proximity with the polypyrimidine tract. These sequences 
mainly have an effect in spliceosome assembly (Wagner et al, 2005). An example 
of intronic  splicing  inhibition  is  that  of Polypyrimidine  tract  binding  protein 
(PTB), which upon binding to the polypyrimidine tract binding  site  CUGUGC 
(Spellman et al, 2005), inhibits splicing by preventing the assembly of the U2AF 
on the 3’ splice site (Sharma et al, 2005).
1.5.3  Regulation of gene expression by alternative splicing
Down-regulation of a gene can be achieved in the cell by a mechanism of mRNA 
surveillance  called  nonsense-mediate  decay  (NDM).  NMD  involves  the 
recognition  of a  premature  termination  codon  (PTC)  which  is  localised  -25 
nucleotides upstream of splicing generated exon junction (Lejeune and Maquat,
2005). Many genes have been identified that are regulated by the incorporation of 
a PTC in the mRNA. Alternative splicing that can lead to PTC can be either due 
to mis-spliced products or for down-regulation of a gene. An example of a gene 
with  mis-spliced  transcript  products  that  have  an  incorporated  PTC  that  is 
degraded by NDM  is the  Fibroblast  Growth Factor Receptor 2  (FGFR2)  gene 
(Yeh et al, 2003). On the other hand auto-down-regulation of the gene by NMD 
has been shown to occur in the SR-like protein Tra2-beta (Stoilov et al, 2004).
451.5.4  Alternative splicing and Drosophila Sex determination
The best example that demonstrates the importance of alternative splicing in the 
regulation of gene expression is in the sex determination pathway in Drosophila. 
The sex determination pathway in Drosophila is based on a series of alternative 
splice site events.
The first gene that is alternatively spliced is the Sex-Lethal (Sxl) gene. The 
Sxl gene is expressed shortly after fertilisation by an early promoter found only in 
the  female.  The  gene  is  alternatively  spliced  excluding  exons  2  and  3.  This 
expression however does not occur in the male. The maintenance promoter found 
in both males and females will drive the expression of the  Sxl protein in both 
males and females. The presence of the Sxl protein early in development leads to 
alternative  splicing of the  Sxl  gene  produced  by  the  maintenance  promoter  in 
females that yields a functional protein,  by  splicing out  exon  3.  Exon  3  is  an 
unusual exon of the Sxl gene because it contains a stop codon. On the other hand 
in the male, a truncated non-functional protein is expressed, due to the absence of 
the  Sxl  expressed  early  in  development.  The  presence  of the  Sxl  protein  in 
females then regulates the alternative splicing of tra2 , a splicing regulation factor, 
by splicing out yet another stop codon from exon 2  and leading to the production 
of a functional protein. Due to the absence of the Sxl in the males a truncate non­
functional  form  of  tra2  is  expressed.  The  presence  or  absence  of tra2  then 
regulates the alternative splicing of the doublesex (dsx) gene that determines the 
sex of the offspring. In the females, the protein contains exons 1  through 4. In the
46males however, the protein contains exons 1  through 6 but exon 4 is spliced out 
(Pomiankowski et al., 2004).
1.5.5  SR proteins and alternative splicing
Another property of the SR proteins is to affect alternative 5’  and 3’  splice site 
selection.  Overexpression  of both  SF2/ASF  and  SC35  favours  proximal  over 
distal 5’  splice site selection.  Furthermore, this property is antagonised  in both 
cases by heterogeneous  nuclear ribonucleoprotein (hnRNP)  Al  (Krainer et al., 
1990;Caceres et al, 1994). Both SF2/ASF (Eperon et al.,  1993;Sun et al.,  1993) 
and SC35 (Liu et al., 2000;Zahler et al, 2004) have been shown to facilitate such 
a  selection  by  binding  to  exonic  splicing  enhancer  and  therefore  recruit  the 
UsnRNPs to the site of splicing. In the case of SF2/ASF, the recognition property 
of the proximal 5’ splice site lies in the RNA Recognition Motif (RRM) 2 and not 
in the RS domain (van Der Houven Van Oordt et al., 2000).  Proximal over distal 
splice site selection also occurs in the 3’ end of the splice site, an effect however 
that is not antagonised by the hnRNP Al  (Fu et al.,  1992).  Finally,  SC35  can 
autoregulate its own expression by alternative splicing. Overexpression of SC35 
led to an exon exclusion and an intron excision in the 3’ untranslated region on its 
endogenous mRNA leading to the production of a very unstable mRNA molecule 
that  was  degraded  (Sureau  et  al.,  2001),  leading  to  a  lower  production  of 
endogenous SC35.
471.5.6  Alternative splicing and disease
Alternative splicing of a gene due to a mutation on an intron site or branch site or 
due  to  abnormal  expression  of  a  splicing  factor  can  lead  to  disease. 
Approximately  15%  of  mutations  that  cause  genetic  disease  affect  splicing 
(Krawczak  et  al,  1992).  Examples  of  disease  caused  by  such  splicing 
abnormalities  include  P-thalassemia,  myotonic  dystrophy,  spinal  muscular 
atrophy, retinitis pigmentosa, atypical cystic fibrosis, Frasier syndrome and even 
malignancy (Faustino and Cooper, 2003;Garcia-Blanco et al, 2004). Furthermore 
regulation  of  splicing  is  essential  for  normal  heart  development  (Cooper, 
2005;Ladd et al., 2005), brain development (Lins and Borojevic, 2001), kidney 
development (Charlet-Berguerand et al, 2004), and skeletal muscle development 
(Cheema et al, 2005).
SR  proteins  are  often  the  cause  of disease  or  the  cause  of abnormal 
development in some cases.  Some examples of the  SR protein involvement  in 
alternative splicing are given below. ASF/SF2 was shown to be an essential factor 
for normal heart development. Cardiomyocytes deficient in ASF/SF2, produce an 
alternatively  spliced  calmodulin-dependant  kinase  Ii8 ,  which  lead  to 
hypercontraction of the heart due to abnormal development (Xu et al, 2005).
SC35 has also been involved in disease and development. SC35 deletion from the 
thymus, leads to alternative splicing of CD45 which causes a defect in the T-cell 
maturation due to the thymus only developing to 10-30% of its normal size (Wang 
et al, 2001). SC35 is also suggested to be involved in certain cases of Alzeimer’s
48disease. It is suggested by Hernandez and colleagues that SC35 is involved in the 
abberant splicing of tau exon 10, of the glycogen synthase kinase 3 (Hernandez et 
al, 2004).
Finally, SR proteins and alternative splicing are implicated in breast and 
ovarian  cancers.  Alternative  splicing  of  CD44  is  believed  to  be  caused  by 
Tra2beta,  SC35  and  ASF/SF2,  which  are  shown to  be  overexpressed  in these 
cases of cancer (Fischer et al., 2004).
1.6  Synopsis
In this introduction I have highlighted the mechanisms of mRNA splicing. The 
experiments  that  follow  present  the  development  and  characterisation  of  a 
fluorescent probe that allows the measurement of splicing efficiency in single cell 
embryos. These two particular SR proteins were selected to be investigated due to 
their  opposing  functions.  SC35  is  an  activator  of splicing  and  is  involved  in 
enhancer-dependent splicing. The organisation of SC35 in nuclear “speckles” as 
well  as  their  involvement  in  splicing  were  investigated.  Following  the 
construction of the Ml M2 probes, the monitoring of enhancer-dependent splicing 
could be investigated, but failure to deplete  SC35  from embryos did not allow 
such experiments to be performed. On the other hand SRp38 is a potent inhibitor 
of splicing. Its role in early development was investigated by the overexpression 
of a  fusion  SRp38-EGFP  protein  or  by  SRp38  depletion  using  morpholinos. 
However,  the  expected  splicing  inhibition  was  not  observed  during  SRp38 
overexpression.
492. Materials and methods
2.1  Oocyte and embryo collection
Immature (germinal vesicle stage) oocytes were retrieved from the ovaries of 21- 
24 day old female MF1  mice that had been administered a 7 IU intraperitoneal 
injection  of pregnant  mare  serum  gonadotrophin  (PMSG;  Intervet)  48  hours 
earlier. Mice were kept in a light/dark cycle with free access to food and water. 
Prior to  removal  of the  ovaries,  the  mice  were  culled  by  cervical  dislocation. 
Ovaries  were  placed  in  warmed  HEPES-buffered  KSOM  medium  (H-KSOM) 
(Summers et al.,  2000) containing  1  mg/ml  fraction V BSA (Sigma Chemicals, 
Poole, Dorset, UK) with 200pM IBMX (Sigma UK) to prevent germinal vesicle 
breakdown, and maintained at 37°C. Oocytes were recovered by puncturing the 
surface of the ovary with a 27-gauge needle, collected using a mouth-operated 
pipette, and placed in drops of media under oil to prevent evaporation (Mineral 
oil; embryo tested, Sigma UK). Only oocytes with an intact layer of cumulus cells 
were  recovered,  and  cumulus  cells  were  subsequently  removed  by  repeated 
pipetting with a narrow pipette.
To recover mature (Mil) oocytes, human Chorionic Gonadotrophin (hCG; 
Intervet)  was  administered  48-54  hours  after  PMSG.  Mice  were  culled  and 
oviducts removed 14-16 hours post-hCG. Cumulus masses were released into H-
50KSOM  by tearing the  oviduct using  forceps.  Cumulus  cells  were  removed by 
addition of hyalauronidase (300pg/ml;  embryo tested grade,  Sigma UK) to the 
media. Following recovery, oocytes were washed through at least three drops of 
hyalauronidase-ffee HKSOM under oil.
For recovery of pronucleate embryos, female mice were mated with males 
at the time of hCG administration. The embryos were recovered from the oviduct 
by the same method as for mature eggs, 26-28h after hCG and mating. Embryos at 
the two-cell stage were recovered 48 hours after hCG and mating.
Oocytes  and  embryos  that  were  not  immediately  utilised  were  left  to 
undergo oocyte maturation and embryo development, respectively, in KSOM at 
37°C in an atmosphere of 5% CO2 in air.
2.2  Microinjection
Embryos were microinjected at 26 hours post hCG (pronucleus stage) or at -50 
hours post hCG (middle 2-cell stage).  They were placed in a drop of HEPES- 
buffered KSOM under oil and pressure injected with a micropipette and Narishige 
manipulators mounted on an inverted microscope (Leica, Wetzlar, Germany). A 
holding pipette was used to immobilise the embryos and the injection pipette was 
pushed  until  inside  the  nucleus  of  one  of  the  blastomeres.  A  brief 
overcompensation of negative capacitance was used to penetrate the plasma and 
nuclear membranes. A fixed pressure pulse was used for microinjection, using a 
picopump  (WPI,  Sarasota,  FL).  The  same  technique  was  performed  for  the
51cytoplasmic injections. However, the injection pipette was only pushed through 
the  zona pellucida  and  in  contact  with  the  plasma  membrane  before  negative 
capacitance was used. The picopump was set up to deliver an injection of ~ 5% of 
cell volume of the vector in the nucleus and -10% of the cell volume of mRNA or 
oligos in the cytoplasm.
After microinjection, the oocytes were removed to the hot block in fresh 
drops of H-KSOM under oil and allowed to recover for a few minutes before any 
other manipulation.
2.3  Probe construction
EGFP  was amplified from base  616 to  base  1330 using the pEGFP-Cl  vector 
(Clontech, Inc., UK) as a template, the 5’  primer GAC  GCG GAT CCG TGA 
GCA AGG GCG AGG A and the 3’ primer  CAG GAT CTA GAT TAC TTG 
TAC AGC TCG TCC. The PCR product was subcloned into the pDsRed Express 
- C l  (Clontech,  Inc.,  UK)  in  the  restriction  sites  BamHI  and  Xbal.  These 
restriction sites were incorporated in the primers. The TN24 intron was described 
by (Nasim et al, 2002). The intron was amplified using the published vector as 
template and primers for 5’  GAT CTC GAG TAC TCC CTC TCA AAA GCG 
GGC and for 3’  GAC GCG GAT CCC TTC TCC  GCC TGA GCC TCA.  The 
amplified intron was subcloned into the DsRed Express -  EGFP vector using the 
Xhol and BamHI restriction sites. The Ml M2 and M1M2AE vectors were also 
subcloned  in  the  DsRed  Express  -   EGFP  using  restriction  sites  Hindlll  and
52BamHI.  The Ml M2 intron was amplified using the 5’  primer TAC  CCA AGC 
TTT ACA AGG TAG TAT GTT GTG GGG CTG and the 3’  GAC GCG GAT 
CCA ATA AGT TTA TAG ACT GCG GCC GA . The M1M2AE was amplified 
by 5’ primer TAC CCA AGC TTT ACA AGG TAG TAT GTT GTG GGG CTG 
and 3’ primer GAC GCG GAT CCA ATA AGT TTA TAG ATG CTG AGA GT. 
The TN24 mutated intron was amplified without the 5’  splice site using the 5’ 
primer TAC CCA AGC TTT ACT CCC TCT CAA AAG CGG  and  the  3 ’ 
primer CAG GAT CTA GAT TAC TTG TAC AGC TCG TCC. The intron was 
then subcloned using the Hindlll and BamHI restriction sites. To ensure cloning 
success,  all  vectors  were  verified  by  sequencing  performed  by  PNACL  at 
Leicester  University.  All  primers  described  in  this  thesis  were  prepared  by 
Invitrogen UK or USA. (For sequences of these vectors see Appendix I).
2.4  Production of Probe mRNA
A PCR reaction was set up using the DsRedEx-TN24-EGFP vector as template, 
and primers 5’  AAA TTA ATA CGA CTC ACT ATA GGG TCA GAT CCG 
CTA GCG CTA CCG and 3’ CAG GAT CTA GAT TAC TTG TAC AGC TCG 
TCC.  The  5’  primer  was  designed  to  include  the  T7  polymerase  promoter 
sequence upstream the start codon of the DsRed Express sequence. The 3’ primer 
was designed to bind to the 3’ end of the EGFP. The PCR product was then used 
as a template for an mRNA reaction using the mMessage mMachine  T7  Ultra 
mRNA kit (Ambion, Texas, USA). The mRNA was polyadenylated as instructed
53by  the  manufacturer  and  was  then  purified  by  Rneasy  column  (Qiagen).  The 
mRNA was finally eluted in Rnase free water, at a concentration of 200-3OOng/pl, 
which was the concentration used for microinjection.
2.5  Western Blotting
For Western blotting,  150 embryos were washed in PBS/BSA solution and then 
they were transferred in 4pi of SDS-sample buffer (0.125M Tris-HCl, 4% SDS, 
2 0 % glycerol,  1 0% mercaptoethanol, 0 .0 0 2 % bromophenol blue) making the total 
sample volune 20pl and then they were frozen on dry ice. After three ffeeze-thaw 
cycles, the samples were boiled for 3-5 min. The samples were then analysed by 
SDS-PAGE (10% gel, running time: 3h at 120V; Table 2.1).  The samples were 
then  transferred  onto  a  PVF  Immobilon-P  membrane  (Millipore)  using  a  wet 
transfer method. The membrane was initially rinsed in methanol followed by a 
wash in water and was finally soaked in transfer buffer (6.06g Tris, 28.8g glycine, 
400 ml of methanol in 2 litres). The transfer apparatus was then setup as followed; 
3  3M papers soaked in transfer buffer, the  SDS-Page gel, the membrane and 3 
more 3M papers. The transfer was run at constant 500mA, maximum volts for 2 
hours at 4°C. The membrane was then placed in Block buffer (3% BSA,  lml/1 
Twin in PBS) for 1  hour at room temperature. This was followed by the antibody 
staining at 1:500 concentration in Block solution overnight at 4°C. The membrane 
was washed 3 times in wash solution (Twin lml/1 in PBS) for 10 minutes at room 
temperature.  The membrane was then placed in the secondary antibody goat anti­
54rabbit  IgG  HRP  (Sigma)  at  a  concentration  of  1:3000  in  block  buffer  for  30 
minutes at room temperature. The final wash was performed by three washes in 
wash  buffer  for  10  minutes.  The  immunostained  bands  were  detected  by 
chemiluminescence (Pierce).
Table 2.1  10% SDS-PAGE gel
Separating gel 10% Stacking gel 4%*
40% acrylamide: 24ml 40% acrylamide: 3 ml
2% Bis-acrylamide: 13ml 2% Bis-acrylamide: 1.5ml
1.5M Tris-HCl pH 8 .8 : 25ml 0.5M Tris-HCl pH 6 .8 : 7.5ml
10% SDS: 1ml 10% SDS: 300pl
10% APS (lg/ml): 500pl 10% APS (lg/ml): 150pl
TEMED: 50pl TEMED: 30pl
Water to 100ml Water to 30ml
* The stacking gel is applied after the separating gel has solidified.
2.6  Construction of the SRp38-EGFP fusion protein
We  have  constructed  a  SRp38-EGFP  chimera  to  follow  the  behaviour  and 
localisation of SRp38 in living mouse oocytes during early development. The use 
of GFP tagged proteins bypasses the problem of the artefacts that are caused by 
the fixation of cells.  The human version of SRp38  was amplified by using the 
pcDNA 3.1  SRp38 vector (provided by James Manley), the 5’ primer GGC TCG 
AGA TGT CCC GCT AC and the 3’ primer GGA ATT CGG CCA CTG GAC
55TT.  The  human  version  of  SRp38  is  100%  identical  in  sequence  with  the 
equivalent mouse proteins Fusip  1   and NSSR  1.  Upon amplification, the insert 
was  subcloned in pEGFP-Nl,  using the restriction  sites Xhol  and EcoRL  The 
SRp38-EGFP  vector  was  expressed  in  embryos  by  direct  injection  into  the 
embryo nucleus. However, mRNA was also produced using the same procedure 
described for the probe mRNA production.  The PCR reaction that was used to 
incorporate the T7 promoter into the product used the primers for 5’ AAA TTA 
ATA CGA CTC ACT ATA GGG ATG TCC CGC TAC CTG CGT CCC and for 
3’ GAT CTA GAG TCG CGG CCG CTT TAC.
2.7  Depletion of SRp38 using Morpholino oligonucleotides
In order to study the action of proteins it is often desirable to deplete the specific 
protein. The most common way to study the action of a specific protein in mouse 
oocytes  is  by  specific  mRNA  degradation  mediated  by  double-stranded  RNA 
(dsRNA),  which  is  termed  RNA  interference  (RNAi)  (Wianny  and  Zemicka- 
Goetz,  2000;Svoboda  et  al,  2000).  In  our  experiments  we  used  Morpholino 
antisense oligos (Gene Tools, USA) which have been shown to be both effective 
and non-toxic  for mouse oocytes.  An antisense  oligo  is designed to  bind to  a 
complementary  sequence  in  the  selected  mRNA.  This  binding  prevents  the 
translation  of that  specific  mRNA  and,  as  a  consequence,  the  protein  product 
coded  by  that  particular  mRNA  is  not  made.  Morpholinos  are  very  stable, 
specific, non-toxic, water soluble and have long-term activity. Their stability is
56due to  their  structure.  Morpholinos are  comprised  of nucleotides  of which the 
riboses are transformed into morpholines through the introduction of an amine. 
The bases  are, thus,  attached to  a morpholine  instead  of a ribose  (www.gene- 
tools.com).
We microinjected specific morpholino oligos to block the expression of 
both SRp38  in mouse oocytes.  The  sequence  of the  SRp38  oligo used was  5’ 
CGG GCT CGG GCA AAC CGT CCG CAG C.  Morpholinos are designed to 
bind to the 5’ UTR. The identification of the specific sequence took into account 
that morpholino oligos work more efficiently when they bind to as much possible 
of the 5’ untranslated region of the target mRNA and when their length is 20-25 
bases  long.  In addition,  we made  sure that the  selected  sequence had no  self­
complementarity to avoid intrastrand pairing. The mouse SRp38 mRNA-specific 
Morpholino was prepared for us by Gene Tools (OR, USA).
To control for possible non-specific effects of the  SRp38 morpholino,  a 
control Morpholino was also purchased. The sequence was CCT CTT ACC TCA 
TTA  CAA  TTT  ATA.  This  oligo  has  no  target  and  no  significant  biological 
activity (www.gene-tools.com).
2.8  Immunolocalisation of SRp38 and SC35
Oocytes or embryos were fixed in freshly-prepared 4% paraformaldehyde (in PBS 
pH  7.4,  lmg/ ml  polyvinyl  alcohol;  PVA)  for  20  min.  After three  washes  in 
PBS/PVA for 5  minutes, the cells were permebilised in 0.2% Triton X-100 (in
57PBS/PVA) for 15 min. The cells were then incubated in blocking buffer (PBS, 2% 
BSA, 0.2% glycine, 0.02% gelatine) for two hours at room temperature (RT) and 
then in the rabbit polyclonal anti-human SRp38 antibody (2.5 pg/ml; provided by 
James Manley) or the mouse monoclonal  SC35 (3pg.ml;Sigma)  in wash solution 
at 4°C over night. The cells were then washed 3 times for five minutes in the wash 
solution described above and incubated with a Alexa conjugated anti-rabbit or 
anti-mouse  secondary  antibody  (0.5  mg/ml;  Alexa  Fluor  488  from  Molecular 
Probes) for one hour at RT. This was followed by extensive washing. Included in 
the  first  wash  was  Hoechst  (for  DNA  staining).  The  immunostaining  was 
visualised  using  a  LSM  510  META  confocal  microscope.  To  ensure  that 
comparisons of immunofluorescence could be made between treatment groups or 
developmental  stages,  the  different  samples  were  scanned  and  viewed  with 
identical settings. Control oocytes or embryos were also stained by following the 
same procedure but omitting the stage of the primary antibody.
Analysis of the data obtained by Immunolocalisation was performed using 
the Metamorph software. Data of average intensity was collected by averaging the 
pixel intensity of two areas of 20*20 pixels in nuclei and two 50*50 pixel areas in 
the cytoplasm.  The size of speckle was measured using the  same software, by 
selecting the speckles and calculating their size, assuming that an oocyte is 80pm 
in diameter and an embryo  is  90pm  in  diameter.  Size bars  are therefore  only 
shown in enlarged images.
582.9  Fluorophores
The  two  fluorescent  proteins  EGFP  and  DsRed  Express  that  are  used  in  the 
experiments presented  in this  thesis have  mutation  compared to  the  wild  type 
proteins.  These mutations are important for the  stability, folding,  solubility and 
time of expression of the protein. The mutations of the EGFP compared to the 
wild type include an insertion of Valine in position 2 of the protein, a Phe-64 to 
Leu,  a  Ser-65-Thr  and  a  His-231-Leu  (Clontech,  UK).  DsRed  Express  also 
contains a series of mutations which aid in the stability, folding time similar to 
EGFP compared to the wild type folding time of 24h,  enhanced solubility and 
reduction of tetramer aggregation. The mutations include Arg-2-Ala, Lys-5-Glu, 
Asn-6 -Asp,  Thr-21  -Ser,  His-41-Thr,  Asn42-Gln,  Val-44-Ala,  Cys-117-Ser  and 
Thr-217-Ala. The spectral properties of the two proteins are shown below.
Table 2.2 Spectral properties of EGFP and DsRed Express
Fluorescent
Protein
Quantum Yield
Extinction Coefficient 
(M 'W 1 )
Relative
brightness
EGFP 0.70 23,000 1 .0 0
DsRed Express 0.90 19,000 1.06
Data obtained from Clontech UK
592.9.2  Fluorescence imaging
The embryos were placed in a drop of HKSOM under oil in a heated chamber 
(37°C)  with  a  cover  slip  on  the  base.  The  chamber  was  mounted  on  a  Zeiss 
Axiovert microscope  (Zeiss,  Welwyn  Garden  City,  United  Kingdom).  DsRed 
Express was excited for 300 msec through a 546/12nm filter using a xenon lamp 
as a source of light and emission was collected through a 590 nm long pass filter 
placed in front of a cooled charge-coupled device camera (CoolSnapHQ, Roper 
Scientific, Tucson, AZ, USA). EGFP was excited for 100 msec though a 480/40 
filter and the emission was collected using a  535/50nm  filter.  Acquisition and 
emission  was  controlled  by  a  PC  computer  running  the  Metafluor  program 
(Universal  Imaging,  Downingtown,  PA,  USA).  The  blastomere  that  was 
expressing the vector was selected and red and green fluorescence levels above 
the system background were collected for each embryo. The fluorescence of the 
blastomeres  was  normally  recorded  at  1  hour  intervals  according  to  each 
experiment. For the experiments involving the SRp38 overexpression, four areas 
in the cytoplasm were selected and the average of these four areas was used for 
analysis.
To ensure that there is no bleed-through of either protein to the other channel, 
control  experiments  were  performed  using  the  purified  recombinant  proteins. 
When different amounts of EGFP were injected in embryos, there was no green 
bleed-through in the red channel. The fact that there is no bleed through of red
60into the green channel can be seen in the experiments of the mutated intron, where 
no red fluorescence is recorded in the green channel.
2.10  Confocal microscopy
Confocal imaging was preferentially used for immuno-localisation experiments of 
SRp38, SC35 and for the experiments of live oocytes and embryos expression the 
SRp38-EGFP.
The advantage of confocal light microscopy is that it can collect the light emitted 
by a single optical plane of the specimen. A pinhole conjugated to the focal plane 
obstructs the light coming from objects outside the plane, so that only light from 
in-focus objects can reach the detector. A laser beam scans the specimen pixel by 
pixel and line by line. The pixel data are then assembled into an image that is an 
optical  section through the  specimen,  distinguished  by  high  contrast  and  high 
resolution  in  x,  y and z.  In order to  reduce background  noise  in the  obtained 
images we used the Kalman averaging function of the confocal microscope. Three 
successive scans of an image were preferred for Kalman averaging.
For  SRp38-EGFP  localisation  during  early  development,  confocal  microscopy 
was performed using  the LSM 510 confocal system.. The system is comprised of 
a Zeiss Axiovert 200M (equipped with ICS  optics  and  supported by the  LSM 
software) and the LSM laser and scanning module.  The oocytes or embryos were 
placed  in  a  heated  chamber  (37°  C)  and  SRp38-EGFP  was  excited  using  the 
488nm line of an argon laser. Fluorescence was collected by a BP 505-530 nm for
61emission, collected through a 20x 0.75 NA objective. Laser power was set to 1  or 
3% of maximum and images were collected at different intervals depending on the 
experiment.
An  Alexa-conjugated  polyclonal  anti-rabbit  or  anti-mouse  secondary  antibody, 
and  Hoechst  were  used  for  detecting  the  anti-SRp38  antibody,  the  anti-SC35 
antibody  and  the  chromatin  respectively,  in  the  cell.  The  LSM  510  confocal 
system  was  used  again  for  imaging  of these  dyes.  For  the  Alexa-conjugated 
antibody, confocal images were taken using the 488 nm laser line of an Argon 
laser and a BP 505-530 nm for emission, using the same set up as SRp38-EGFP 
imaging. For imaging Hoechst, confocal images were obtained by exciting with 
the 351 nm laser line of a UV laser and emission was collected through a BP 435- 
485 nm.
For  all  confocal  imaging  experiments a pinhole  of 2.22  Airy  Units was  used, 
giving  a  calculated  optical  slice  of 3.5pm.  The  images  were  analysed  using 
Metamorph software.
2.11  Statistical analysis
All  t-tests  are two-tailed and based  upon two  samples  (unpaired)  with  similar 
variance. Where shown on figures, error bars represent the standard deviation.
62Table 2.3  Spectra of Fluorophores used
Fluorescent Agent  Excitation Maximum (nm)  Emission maximum (nm)
Alexa or EGFP  488  507
DsRed Express  557  579
Hoechst  350  450
Table 2.4  PCR Reaction Reagents
Agent Concentration Amount
Template 2 0  ng / pi 1 pi
Primer Forward/ Reverse 100 pM 0.5 pi
dNTPs 10 mM 0.5 pi
10* Buffer - 5 pi
Biology Grade Water - 42.5 pi
Taq Polymerase 5 units / pi 0.5 pi
Annealing temperature was set at 5°C below melting temperature of the primers 
used  in  the  reaction.  The  primers  were  designed  using 
http://www.promega.com/biomath/calcl 1 .htm.
63Table 2.5  Concentrations of Injectable reagents
Agent  Concentration in the pipette
Splicing probes  200 ng / ml
U1 Oligonucleotide  1  mM
Morpholinos  1  mM3. Development of a fluorescent probe to 
measure mRNA splicing in single living cells
3.1  Introduction
Most genes in higher eukaryotes contain non-coding sequences,  introns,  which 
need to be excised from the pre-mRNA molecule to generate the mature molecule. 
This process is called mRNA splicing. The major-class splicing pathway involves 
five small nuclear ribonucleoprotein particles that recognise consensus sites in the 
5’ and 3’ splice sites of the pre-mRNA molecule. Together with proteins involved 
in excising and ligating of the pre-mRNA molecule they form a complex called 
the spliceosome. Excision and ligation of the 5’ and 3’ splice sites is catalysed by 
a series of RNA-RNA, RNA-protein and protein-protein interactions. The mature 
mRNA molecule is then exported to the cytoplasm where translation takes place 
(Patel and Steitz, 2003) (See section 1.3).
Splicing  abnormalities  are  implicated  in  disease  and  are  necessary  for 
normal embryonic development. Point mutations in the coding DNA can cause 
silent or missense mutations.  However, when mutations occur in critical  splice 
sites, frameshift and nonsense mutations can completely alter the coding sequence
65of the gene. Examples of disease caused by such splicing abnormalities include 1 3 - 
thalassemia, myotonic dystrophy,  spinal muscular atrophy, retinitis pigmentosa, 
atypical  cystic  fibrosis,  Frasier  syndrome  and  even  malignancy  (Faustino  and 
Cooper, 2003;Garcia-Blanco et al, 2004). Furthermore regulation of splicing is 
essential  for development of many organs and tissues  including heart (Cooper, 
2005;Ladd  et  al,  2005),  brain  (Lins  and  Borojevic,  2001),  kidney  (Charlet- 
Berguerand et al, 2004), even skeletal muscle (Cheema et al, 2005).
mRNA  splicing  may  also  play  an  important  role  in  early  mammalian 
development.  Transcription  is  switched  off during  the  final  stages  of  oocyte 
maturation and starts again at a specific time after fertilization (late  1-cell -  2 -cell 
stage in the mouse, 4-8-cell stage in the human). This implies that splicing may 
also be developmentally regulated during this period. Furthermore, if splicing is 
regulated during this period then the early embryo may prove to be a useful model 
for investigating the regulation of mRNA splicing and spliceosome assembly. To 
date no experiments have been performed to investigate the control and regulation 
of mRNA splicing during the activation of the embryonic genome.
There are two conventional types of assay for splicing efficiency currently 
in  use.  Firstly,  assays  are  performed  by  transfection  of  gene  fragments  to 
mammalian cells. The resultant mRNA molecules are analysed by means of RT- 
PCR. The sizes of the RT-PCR fragments allow the determination of spliced or 
unspliced product. The splicing efficiency can be calculated as the ratio of spliced 
:  unspliced  mRNA  (Lytle  and  Steitz,  2004).  Secondly,  in  vitro  assays  are
66performed by adding radioactively labelled mRNA transcripts to nuclear extracts. 
The  intermediate  stages  and products  of splicing  are  then  visualised  by  urea- 
PAGE electrophoresis and autoradiography (Mayeda and Krainer,  1999). A ratio 
of spliced and unspliced mRNA can then be calculated from the  intensities of 
spliced and unspliced mRNAs. These methods are reliable and straight forward, 
but lack the ability to monitor splicing in single cells or in a dynamic system, such 
as development.
Two  different approaches  have been  reported  recently that  allowed  the 
measurement of splicing activity in live cells.  This was firstly demonstrated by 
construction  of  an  EGFP  minigene.  This  minigene  contained  an  intron  that 
intervenes  the  EGFP  reading  frame.  Cell  lines  were  then transfected  with  the 
EGFP construct. Splicing activity would then be determined by fluorescence of 
the  EGFP  protein,  whereas  splicing  inhibition  would  lead  to  expression  of a 
truncated protein and therefore no fluorescence (Sazani et al., 2003;Wang et al., 
2004).  However, such a system does not provide an internal reference that would 
yield internal information of transcription level or transfection efficiency.
In 2002, Nasim and colleagues described an elegant approach to monitor 
splicing activity in cultured mammalian cells. The group constructed a reporter 
vector containing the reading frames of p-galactosidase and luciferase, separated 
by  an  artificial  intron.  This  intron  comprised  an  exon-intron  (5’  splice  site) 
sequence  donated  from adenovirus, three in frame  stop  codons,  and an intron- 
exon (3’ splice site) sequence donated from the human tropomyosin TPM3 gene.
67All transfected cells express the P-galactosidase gene. The enzymatic activity of 
P-galactosidase  indicates  reference  transcription  and  translation  levels  of the 
reporter. However, only cell lines in which splicing has taken place express the 
luciferase gene. In the absence of splicing, the translation is terminated at the stop 
codon, present between the 5’ and 3’ splice site of the reporter. Splicing efficiency 
was  then  calculated  as  a  ratio  of the  enzymatic  activities  between  the  two 
enzymes.  This  assay  allows  splicing  efficiency  to  be  determined  in  live 
mammalian cells, but it unfortunately requires the destruction of the cells and for 
the measurement to be performed on populations of cells rather than single cells.
In order to study the mRNA splicing in single living mammalian embryos, 
we set out to design a fluorescent probe for mRNA splicing. To construct such a 
reporter, we substituted the two enzymes in the reporter described earlier (Nasim 
et al., 2002) with two fluorescent proteins, DsRed Express and EGFP.
In  this  chapter  I  describe  the  preparation  and  characterisation  of  a 
fluorescent splicing sensor. Here we show that the splicing sensor can be used to 
monitor splicing activity in single living cells. We have used this probe to show 
that interfering with splice site during activation of the embryonic genome results 
in inhibition of embryo development at the 2 -cell stage.
683.2  Results
3.2.1  Characterisation of the probe
The production of the probe was achieved by a series of sub-cloning experiments 
outlined in section 2. The general principle of how the probe operates is shown in 
Figure 3.1 A.  DsRed Express (RFP) is located downstream of a CMV promoter 
that  drives  transcription  in  the  nucleus  of  the  early  embryos.  The  intron 
encompasses three in frame translational stop codons. In the absence of splicing, 
translation ends after RFP, thereby providing fluorescence exclusively from RFP. 
In the presence of splicing the translational machinery will read through to the 
EGFP, thereby providing fluorescence from RFP and EGFP.
To  test  the  principle,  we  constructed  a  vector,  DsRed  Express-TN24- 
EGFP, by cloning EGFP into the multiple cloning site of DsRed Express and then 
inserted  the  test  intron  from plasmid  pTN24  (Nasim  et al,  2002).  The  TN24 
intron contains a 5’  exon-intron sequence from adenovirus and a 3’  intron-exon 
sequence  from  the  tropomyosin  TPM3  gene.  To  ensure  that  both  fluorescent 
proteins are only apparent when splicing has taken place, the EGFP sequence in 
the  complete  construct  is  out  of frame  with the  upstream  RFP  reading  frame. 
Therefore, EGFP becomes in frame with the upstream coding sequence, only after 
splicing has taken place.
The  probe  was tested by  microinjection  of the  DNA  into  the  nuclei  of 
single blastomeres of 2-cell embryos. The embryos were cultured for 8 hours and 
then  examined  using  appropriate  filter  sets  and  epi-fluorescent  microscopy
69(Figure  3.IB).  The probe  is expressed  in the  injected blastomere.  The  relative 
levels of splicing (EGFP intensity) as a function of transcription (RFP intensity) 8  
hours  after  injection  are  plotted  in  Figure  3.1C.  Each  point  represents  an 
individual embryo. If the reporter assay compensated for variation in the level of 
expression, it would be predicted that the intensity of EGFP fluorescence (spliced 
mRNA)  would  be  proportional  to  the  intensity  of  RFP  fluorescence  (total 
expressed mRNA). The data in figure 3.1C fits these results. The most probable 
explanation of the different levels of transcription may reflect variations in the 
amount  of DNA  injected  and  different  transcriptional  activities  in  individual 
embryos.
The data show that the fluorescence detected as a result of transcription 
(RFP)  is  markedly  less  than  the  fluorescence  obtained  from  spliced  product 
(EGFP). For example, fluorescence as a result of transcription of RFP is at  100 
AU correlates with a value of spliced product EGFP of 300 AU. Even if 100% of 
the mRNA were spliced, the number of molecules of EGFP should not exceed that 
of RFP. In our experimental conditions we found that RFP fluorescence intensity 
was — 2-3 fold lower than EGFP fluorescence, despite a 3-fold large acquisition 
time for RFP. To determine whether this was a property of relative fluorescent 
intensities of EGFP and RFP or if it was a property of the probe, a standard curve 
was prepared by injecting equal amounts of recombinant purified EGFP and RFP 
across a range of concentrations (Figure 3. ID). This clearly shows that for the
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71same concentration of protein, EGFP is brighter than REP (Clontech), consistent 
with the experimental data obtained using this probe.
3.2.2  Monitoring the time course of expression and splicing
To  monitor transcription  and  splicing,  we  injected  the  reporter and monitored 
fluorescence every hour from 3  hours after injection.  The increase in RFP  and 
EGFP fluorescence with time shows that transcription and splicing continue over 
the  8 hour time period (Figure 3.2A). Using the standard curve shown in Figure 
ID,  the  RFP  fluorescence  values  have  been  corrected  so  as  to  allow  splicing 
efficiency  to  be  compared  more  readily  across  a population  of embryos.  This 
corrected  value  was  obtained  by  introducing  the  RFP  value  into  the  equation 
y=2.3x+82. This correction is applied to all RFP data presented from this point on. 
After correction, the expectation would be that  100% splicing efficiency would 
result in overlapping RFP and EGFP. In the single embryo shown in Figure 3.2B 
and in the normalised data for 6 embryos, it is clear that 5-6 hours after injection 
of the plasmid the levels of RFP and EGFP proteins diverge. The relative decline 
in EGFP intensity suggests that the rate of splicing does not continue to match 
transcription. By plotting the apparent splicing efficiency (EGFP (Spliced) / RFP 
(Transcribed)) a gradual decrease is seen such that it is approximately 70% by  8  
hours  after  injection.  One  possible  explanation  for  this  gradual  decrease  in 
splicing  efficiency  is  that  the  level  of  transcription  saturates  the  splicing 
machinery.
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733.2.3  The probe works using different intronic sequences
The intron used to date, TN24, is a construct using an exon-intron sequence from 
Adenovirus and an intron-exon sequence from tropomyocin (Nasim et al., 2002). 
To test whether other introns function in a similar manner, we produced a vector 
containing  an  exon-intron-exon  sequence  from  IgM  gene  (MlM2).  A  second 
vector was generated that has the same intron, but it lacks a downstream enhancer 
sequence (M1M2AE) (Liu et al., 1998;Liu et al., 2000;Nasim et al., 2002) (Figure 
3.3A).  Both  these  vectors  include  a  single  stop  codon.  Similar  to  the  TN24 
vector,  the  EGFP  is  out  of frame  with  the  upstream  sequence  of the  DsRed 
Express  in  both  Ml M2  vectors.  After  microinjection  of  the  vectors  into  a 
blastomere  of a  2 -cell  embryo  the  overall  pattern  of expression  and  splicing 
activity for both vectors over 8 hours is similar to that seen for TN24. Figure 3.3A 
presents  a  schematic  of  the  probe  expression  outcome  of  the  Ml M2  and 
M1M2AE vectors.
These  two  probes  provide  an  opportunity  to  investigate  whether  the 
splicing probe is sufficiently sensitive to detect differences between Ml M2 and 
the M1M2AE. The absence of the enhancer sequence in M1M2AE predicts it will 
be spliced less efficiently than Ml M2. This was tested by examining the levels of 
splicing in 2-cell embryos  8 hours after microinjection of the vectors.  In all the 
embryos examined across a range of different levels of transcription, the level of 
splicing is less in the M1M2AE intron than Ml M2. This data shows that the
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Figure 3.3. The effect of an enhancer sequence on splicing. The two probes 
were injected and the embryos were monitored after  8 hours of culture.  The 
graph  shows  the  corrected  fluorescence  levels  of  the  two  probes.  The 
enhancer-less intron (M1M2AE) is shown to be spliced less efficiently that the 
intact intron (MlM2 ).
75fluorescent  strategy  to  monitor  splicing  can  be  used  to  detect  differences  in 
splicing efficiency.
3.2.4  Splicing is necessary to achieve expression of the EGFP
Since the three  vectors described above presented  similar splicing patterns,  we 
have performed further experiments with the TN24 vector to ensure that the EGFP 
fluorescence only appears in conditions where splicing is expected.
Firstly, we have attempted to inhibit all  splicing by removing the 5’  splice site 
from  the  vector.  As  a  result  we  predict  that  RFP  should  be  produced  in  the 
absence of any EGFP (Figure 3.4A). Microinjection of this vector revealed that 
after  8  hours of culture, no splicing activity was evident over a wide range of 
transcription levels (Figure 3.4A). This confirms that the 5’ splice site is essential 
for splicing of the mRNA and that the probe only yields  EGFP when  splicing 
takes place.  As  a  second  test  that  EGFP  fluorescence  was  dependent  on 
splicing,  we  in  vitro  transcribed  mRNA  of  the  probe.  The  mRNA  was 
microinjected  into  the  cytoplasm  of  2 -cell  embryos  and  splicing  activity  was 
monitored.  Since  splicing takes place  in the nucleus,  we hypothesised that the 
injected mRNA would be translated with no evidence of splicing. As predicted, 
we detected RFP, indicating efficient transcription and translation but no EGFP 
(Figure 3.4B). These experiments show that the splicing probe provides a reliable 
measure of mRNA splicing activity in single living cells.
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Figure  3.4.  A.  Comparison  of  splicing  efficiencies  between  the  vectors 
comprising  of  the  TN24  and  the  TN24A5’  (mutated)  introns,  in  single 
blastomeres 8 hours after injection. The vector comprising the TN24 intron is 
spliced as described earlier. No splicing is taking place in the TN24A5’ vector 
with  the  mutated  intron.  5’  splice  site  is  essential  for the  splicing  process. 
This result also indicates that the stop codons are functioning. B. Comparison 
between  splicing  efficiencies  of  the  DNA  injected  in  the  nucleus  of  an 
embryo  and  the  same  mRNA  sequence  injected  in  the  cytoplasm  of  an 
embryo.  DNA  in  the  nucleus  is  spliced  as  expected,  yielding  the  fusion 
protein DsRed Express-EGFP.  The mRNA  injected  in  the cytoplasm yields 
only  RFP  showing  normal  translation  but  no  splicing  activity  in  the 
cytoplasm.
773.2.5  Inhibition of a major snRNP, Ul, inhibits splicing in vivo
Upon  confirmation  that  the  EGFP  fluorescence  could  only  be  detected  in 
conditions that supported mRNA splicing, we  set out to test whether we could 
inhibit splicing in vivo and examine the effects on embryo development.
In  splicing  assays  in  vitro,  splicing  can  be  inhibited  using  an  oligonucleotide 
complementary to the 5’ end of the Ul snRNA (Kramer et al., 1984). This portion 
of the Ul  snRNA recognises the 5’  splice site by base pairing complementarity. 
Ul  snRNA  was  therefore  an  obvious  target  for  inhibition  of the  major-class 
pathway of splicing and provided an opportunity to address the role of splicing in 
embryo development.
The  oligo  complimentary to  Ul  snRNA  was  injected  45h post hCG,  3 
hours prior to the mid 2 -cell stage, and the probe was then injected in the mid 2 - 
cell  stage  as  before  and  the  efficiency  of splicing  was  monitored.  In  control 
embryos injected with scrambled oligo, the typical pattern of RFP and EGFP was 
detected showing normal transcription and splicing. In embryos injected with the 
Ul  oligo  8 hours previously there was a measurable decrease in splicing across a 
wide range of expression levels, using the TN24 (Figure 3.5A), the Ml M2 (Figure 
3.5C) and the M1M2AE (Figure 3.5E).  For example, when RFP fluorescence is 
1000AU, the oligo complementary to Ul reduced EGFP to 20-40% of the control 
(Table 3.1).
Fluorescence records for the time course of transcription and splicing from 
3 hours is shown for representative single embryos in Figures 3.5 B, D, and F. In
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79Vector
EGFP
fluorescence
Relative Splicing 
Efficiency
TN24
Ul Oligo 307
38% Control
Oligo 799
M1M2
Ul Oligo 118
17% Control
Oligo 709
M1M2AE
Ul Oligo 209
33% Control
Oligo 625
Table 3.1. The table demonstrates the decrease in splicing efficiency of the 
Ul oligo injected embryos compared to the controls. The average decrease is 
splicing efficiency was between -60% and -80%  compared to  the  control 
splicing efficiency. The EGFP fluorescence values presented correspond to a 
level of RFP of lOOOAUs.
80all cases the Ul injected embryos show a decline in green fluorescence, consistent 
with  inhibition  of  splicing.  Interestingly,  in  each  case  the  RFP  fluorescence 
increased in Ul oligo injected embryos compared to controls. The shift of red may 
reflect  an  increase  in  export  of  unspliced  transcripts  to  the  cytoplasm  for 
translation in the absence of Ul snRNP binding activity.
3.2.6  Inhibition of Ul dependant splicing prevents development beyond the 
2-cell stage
Transcription necessary for subsequent development first occurs at the mid 2-cell 
stage.  To  date  no  experiments  have  investigated  whether  interfering  with  the 
mRNA splicing impacts on the ability to progress beyond the 2-cell stage. To test 
this hypothesis that splicing is essential for development beyond the 2 -cell stage, 
we  have  injected  the  Ul  oligo,  known  to  block  splicing,  and  monitored 
development. The results clearly show that Ul  injected but not scrambled oligo 
injected embryos all block at the 2-cell stage of development (Figure 3.6). This 
indicates a critical role  for transcription and  splicing  at the time of embryonic 
genome activation.
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Figure  3.6.  Effect  of Ul  oligo  injection  on  development  of embryos. 
Control injected embryos develop normally to the 4-cell stage, whereas Ul 
oligo injected embryos arrest at the 2-cell stage.3.3  Conclusions
This  chapter presents  a novel,  fluorescent based  probe  for monitoring  splicing 
activity in single cells. The disadvantages of the conventional splicing assays are 
that they are biochemical, destructive assays that do not allow the measurement of 
splicing efficiency in a single cell basis in early development. It was demonstrated 
that fluorescent proteins such as DsRed Express and EGFP can mature as quickly 
as three hours after injection of our probes and report  splicing efficiency.  The 
probes are designed in such a way so that both fluorescent proteins are expressed 
only if splicing has taken place. Two measures are used to ensure that only RFP is 
expressed  in  the  absence  of  splicing.  First,  the  stop  codons  in  the  intronic 
sequence downstream of RFP and second that the downstream EGFP is out of 
frame in the complete cDNA.
The  ability  of the  probe  to  detect  changes  in  splicing  efficiency  was 
challenged by inhibition of splicing by the means of a Ul oligonucleotide injected 
before  injection  of  the  probe.  There  was  a  great  reduction  in  the  splicing 
efficiency  of more  that  60%  in  all  cases  after  injection  of the  Ul  oligo.  The 
splicing properties of TN24 were also challenged by mutation of the 5’ splice site 
and injection of mRNA in the cytoplasm, which led to the exclusive production of 
RFP  and  therefore  no  splicing.  The  three  different  probes  that  were  used 
demonstrated that splicing efficiency is highly dependant on the 5’ and 3’ splice 
site  sequences and also  on the presence  or not of an exonic  splicing enhancer 
sequence.
83These probes demonstrated for the  first time the monitoring of splicing 
activity  in  live  cells  during  a  short  time  course.  It  was  shown  that  splicing 
efficiency  could be  monitored  as  soon  as  3  hours  after  injection  of the  DNA. 
Overloading  of the  cell  with  probe  transcripts  and  embryonic  transcripts  may 
explain the decrease in splicing efficiency 5 hours of after injection. Transcription 
was unaffected during this period of 8 hours, as indicated by the linear increase of 
RFP.  This suggests that the rate of splicing and transcription can be uncoupled 
and that there is limited feedback from splicing machinery to control the rate of 
transcription.  These  results  uncover  a  limitation  of this  system.  The  fact  that 
plasmid DNA is injected in the nucleus results in continuous production of probe 
transcripts, which may lead to the proposed saturation of splicing machinery.
Some considerations were raised during the construction of these probes. 
One of them was that unspliced mRNA tends to remain in the nucleus, because 
splicing  factors  that  interact  with  the  pre-mRNA  prevent  its  transport  to  the 
cytoplasm (Legrain and Rosbash,  1989).  Such an effect would be disastrous for 
our assay, because if only spliced mRNA was expressed, it would be impossible 
to  measure  splicing  efficiency.  However,  our  results,  results  by  Nasim  and 
colleagues  (2002)  and  results  from  Legrain  and  Rosbash  (1989)  show  that 
unspliced  mRNA  is  exported  and translated.  The  Legrain  and  Rosebash  study 
demonstrated that a mutation in the Ul  snRNA decreased splicing efficiency and 
caused  a  large  increase  in  translation  of  their  minigene.  Our  experimental 
approach actually mimics the inhibition of Ul  snRNA binding to the pre-mRNA,
84in  a  similar  way  to  that  presented  by  Legrain  and  Rosebash  (1989).  In  our 
experiments the Ul oligo binds to the Ul  snRNA, therefore inhibiting its binding 
to  the  pre-mRNA.  The  fact that  RFP  fluorescence  was  increased  in  Ul  oligo 
injected embryos compared to controls, suggests that when Ul  snRNP does not 
bind to the pre-mRNA, there may be an increase in mRNA export, as shown by 
Legrain  and  Rosebash.  Our  results  also  suggest  that  the  amount  of unspliced 
mRNA that is exported from the nucleus does not depend on splicing efficiency; 
otherwise large variations would be recorded in the levels of red fluorescence with 
similar amounts of the probe being injected.
A second consideration was nonsense mediated  decay (NMD).  NMD  is 
the decay of mRNA containing a premature stop codon after splicing has taken 
place.  The mechanism of NMD compromises mRNA that appears to contain a 
termination  codon ~25  nucleotides  upstream  of a  splicing  exon-exon junction. 
NMD  therefore  provides  a defence  mechanism  to  the  cell  from  truncated  and 
possibly  deleterious  proteins  (Lejeune  and  Maquat,  2005).  However,  NMD 
occurs  only  in  spliced  and  not  unspliced  mRNA.  Therefore  NMD  would  not 
actually occur in our termination codon if proper splicing has taken place, and 
such a process would not interfere with our results.
Development was affected by the inhibition of splicing by compromising 
the  activity  of a  major  snRNP,  Ul.  All  2-cell  embryos  injected  with  the  Ul 
oligonucleotide arrested at the 2-cell stage. The zygotic genome activation occurs 
in the mouse in two phases; in late  1-cell stage and at the second half of the 2-cell
85stage.  Up  until  this  stage  all  mRNAs  required  for  development  have  been 
processed during embryogenesis (Latham, 1999) and their expression is regulated 
by  polyadenylation  (Richter  and  Theurkauf,  2001).  After  zygotic  genome 
activation,  transcription  of  embryonic  messages  requires  splicing  for  proper 
protein  expression.  Our experiments  verified  that  inhibition  of splicing  in that 
stage  results  in  arrest  of  development,  due  to  expression  of  truncated  and 
deleterious proteins in the absence of splicing.
More probes can be designed in such a way that the splicing efficiency of 
different  intron  sequences  can  be  investigated.  An  example  would  be  to  use 
introns that would be spliced by minor class pathway, and determine if, when and 
possibly how these two distinct pathways are important in early development. 
These probes possess a great potential for quick and easy results regarding the 
measurement of splicing efficiencies. These properties allow these probes to be 
very useful in experiments performed in early development, where cell divisions 
occur during short periods of time, due to the quick and easy way of obtaining 
results.
864. The development of nuclear “speckles” in 
early mouse development
4.1  Introduction
Nuclear  “speckles”  are  structures that contain  snRNPs and  SR proteins.  These 
structures are otherwise known as interchromatin granule clusters (IGCs), which 
appear to be important in spliceosome assembly and also act as storage sites for 
factors  essential  for splicing (Lamond and  Spector,  2003).  One  of the  splicing 
factors localising in the nuclear speckles is SC35.
SC35  is  a protein of 35kDa that belongs to  the  SR protein  family.  SR 
proteins are serine-arginine rich proteins or otherwise known as non snRNPs and 
they play a numerous roles in spliceosome assembly and regulation of the splice 
site selection / alternative splicing (refer to section 1.5). SR proteins possess one 
or two N-terminal  RNA  binding  domains (one  in the  case of SC35)  and  a C- 
terminal domain rich in serine-arginine (SR domain), which functions as a protein 
interaction  domain  (Graveley,  2000).  In  transcriptionally  active  cells,  SC35 
localises in the nucleus in structures called nuclear speckles, where most splicing 
factors are localised.  The RS  domain of SC35  is necessary  and sufficient as a 
targeting signal to localise SC35 to the speckles (Caceres et al., 1997). Many SR 
proteins such as SRp20, 9G8 and ASF/SF2 shuttle between the nucleus and the
87cytoplasm  (Caceres et al,  1998), but SC35  is retained in the nucleus due to a 
strong nuclear retention signal on its RS domain (Cazalla et al., 2002).
A  role  for  SC35  in  splicing  was  first  discovered  by  depleting  if from 
nuclear  extracts.  SC35  was  also  shown  to  co-localise  with  snRNPs  (Fu  and 
Maniatis, 1990) and RNA Polymerase II (Bregman et al, 1995) . SC35 is required 
for spliceosome assembly (Fu and Maniatis,  1990)  and it was later shown that 
SC35  interacts with both Ul  snRNP, which binds to the 5’  splice site, and the 
U2AF  and  U2  snRNP,  which  bind  to  the  3’  splice  site  (Fu  and  Maniatis, 
1992;Bruzik, 1996). SC35 can activate splicing in vitro in SI00 HeLa cell extracts 
(Fu et al,  1992), or compensate for the loss of the Ul  snRNP in vitro (Tam and 
Steitz, 1994). Furthermore it can reconstitute splicing in U2AF65 depleted nuclear 
extracts but only in the presence of Ul (Tam and Steitz, 1995). This suggests that 
the SC35 is involved in the selection of 5’  and 3’  splice sites and that there are 
distinguishable mechanisms for the binding of U2 in the pre-mRNA depending on 
whether U2AF is present or not (MacMillan et al, 1997).
SR proteins are generally regulated by phosphorylation. It has been shown 
in  nematodes  that,  in  their  inactive  form  they  are  hyperphosphorylated  and 
localise  in  the  cytoplasm  of the  cell.  After  zygotic  genome  activation,  they 
become active by partial dephosphorylation and localise to the nucleus (Sanford 
and Bruzik, 1999;Sanford and Bruzik, 2001).
SC35 is also implicated in alternative splicing. It was shown that SC35 can 
favour proximal over distal 5’ splice site selection and also influence the 3’ splice
88site selection by favouring the proximal 3’ splice site (Fu et al, 1992). SC35 was 
also shown to have antagonistic effects on SF2/ASF, by inhibiting the splicing of 
a particular exon, in which the splicing was enhanced by SF2/ASF (Gallego et al, 
1997).  Later experiments showed that SC35  enhanced splicing when an exonic 
splicing enhancer sequence was present in the downstream exon (Liu et al, 2000). 
This substrate specificity was shown to be mediated by the RRM domain of SC35. 
This was demonstrated in studies where the RRM domains of SF2/ASF and SC35 
were swapped (Chandler et al, 1997;Mayeda et al, 1999).
SC35 was shown to be induced in cases of human ovarian cancer (Fischer 
et al, 2004) and in HIV infected cells (Maldarelli et al, 1998) and was implicated 
in alternative splicing in both cases. Knock-out mice with a deletion of the SC35 
gene from the thymus, caused a dramatic decrease in the size of thymus and also 
caused the alternative splicing (lack of exon 5 from mRNA) of the CD45 marker, 
which led to severe block in T-cell development (Wang et al, 2001).  SC35 has 
been  implicated  in  a  mental  retardation  cases  caused  by  lactic  acidosis.  A 
mutation  downstream  of exon  7  of El-alpha  dehydrogenase,  caused  SC35  to 
recognise it as a cryptic splice site, causing abberant splicing of the gene (Gabut et 
al, 2005). Finally, the level of SC35  expression is autoregulated by alternative 
splicing, by an exon inclusion and intron excision in the 3’ untranslated mRNA 
region under overexpression conditions. The resulting mRNA is unstable thereby 
causing the reduction of newly synthesised SC35 (Sureau et al, 2001).
89SC35  has  been  shown  to  co-localise  with  a  nuclear  pool  of  PIP2, 
implicating PIP2 in regulation of splicing and spliceosome assembly (Osborne et 
al, 2 0 0 1).  PIP2 is a membrane bound phospholipid found in all eukaryotic cells, 
mainly  in  the  plasma membrane.  PIP2  is  involved  in  many  cellular  processed 
including  the  release  of Ca2+  (Berridge,  1997)  and  the  regulation  of the  actin 
cytoskeleton  (Halet  et  al.,  2003).  The  co-localisation  of  PIP2  with  SC35 
demonstrated by Osbourne and colleagues suggests that PIP2 may play a role in 
pre-mRNA  splicing.  PIP2  was  found  to  co-localise  with  SC35  in  a  speckled 
appearance  within the  nucleus  of the  cell  (Osborne  et al,  2001).  In the  same 
study,  PIP2  depleted  nuclear  extracts  showed  an  80%  decrease  in  splicing 
efficiency, demonstrating a new role of PIP2 in the cell. However, the regulation 
of mRNA processing during early development is not yet clear. Zygotic genome 
activation in the mouse occurs at the second half of the 2-cell stage. Therefore, 
this transition from maternal dependence of the embryo to zygotic dependence 
provides  a transition  in  which  the  importance  of SC35  and  PIP2  during  early 
development and splicing may be investigated.
In this  study,  I  have used  SC35  and PIP2  localisation  in the nucleus to 
investigate the evolution of nuclear speckles during oocyte maturation and early 
embryo development.
904.2  Results
4.2.1  SC35 localisation during oocyte maturation using immunofluorescence
Immunofluorescence techniques were used in order to investigate the localisation 
of SC35 during early mouse development.  To ensure that the immunofluorescent 
images  can  be  compared,  the  staining  of all  oocytes  and  embryos  in  any  one 
experiment  was  performed  at  the  same  time  using  identical  conditions.  The 
localisation of SC35 was investigated in oocytes obtained from pre-antral follicles 
through to embryos at the 8-cell stage. In preantral follicles, SC35 localises in the 
nucleus in multiple small speckles (Figure 4.1 A and Ai). When fully grown GV- 
stage oocytes were stained immediately after collection, small speckles were seen 
within the germinal vesicle 1.4±0.25pm (n=6,) both when collected in IBMX free 
or enriched media (Figure 4.1  B and C respectively). GV-stage oocytes that were 
cumulus-free upon release from the follicle appeared with enlarged speckles of 
2.7±0.8pm in diameter (Figure 4.1 D). When the oocytes were fixed and labelled 
1   hour after collection, the  speckle size was larger, 3.34 ±0.75pm  in diameter 
(n=6)  (Figure  4.1  E).  It  was  also  surprising  to  see that  immature  oocytes 
arrested in  IBMX  for the same  period of time also presented  staining in the 
nucleus in the form of large speckles, 3.26±0.89pm in diameter (n=6) (Figure 4.1 
F). After GVBD, SC35  redistributed to the cytoplasm (Figure 4.1  G), where it 
remained  for the  duration of o ocyte  maturation.  Finally, in  the  Mil  stage, a 
stage  in which the  cell  does not possess  a  nucleus,  SC35  localises  in the 
cytoplasm of the cell (Figure 4.1 H). In
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Figure 4.1. The localisation of SC35 during oocyte maturation. In all images i corresponds 
to  magnified  image  of the nucleus.  A.  Pre-antral  follicle.  SC35  localises in the nucleus  in 
small speckles. B. GV oocyte fixed in IBMX free medium.  Speckles of 1.4pm in diameter 
are  seen  within  the  GV.  C.  An  oocyte  collected  in  medium  containing  IBMX  and  fixed 
immediately after isolation appears with similar speckles as in GV oocyte collected in IBMX 
free medium. D. An oocyte that was cumulus free on release from the follicle.  The oocyte 
appears with larger speckles, 2.7pm in diameter. E. GV oocyte released for 1   hour. Speckles 
are enlarged to 3.34pm in diameter. F. GV oocyte arrested in IBMX for 1   hour. Surprisingly 
enlarged  speckles  3.26pm  in  diameter  are  seen.  G.  After  germinal  vesicle  breakdown 
speckles disappear and SC35 distributes to the cytoplasm. H. MIL SC35 is distributed in the 
cytoplasm. I. A control oocyte, stained only with the secondary fluorescent antibody.
92control GV-stage oocytes (Figure 4.1  I), there was no staining in the nucleus or 
the cytoplasm.
4.2.2  Localisation of SC35 during early embryo development
Immunofluorescence  of  SC35  in  early  embryos  is  shown  in  figure  4.2. 
Differences observed in the nuclear-cytoplasmic ratios during this period can be 
seen  in  figure  4.3.  At pronucleus  stage  (Figure  4.2  A)  (26h  post  hCG)  SC35 
remains  in the cytoplasm of the cell.  Prior to NEBD  (3Oh post hCG),  SC35  is 
recruited to the pronuclei  of the  embryo.  This  is accompanied by  an  apparent 
decrease in immunoreactivity in the cytoplasm (Figure 4.2 B) and an increase in 
nuclear-cytoplasmic ratio (Figure 4.3). At the early and mid 2-cell stage, maternal 
SC35 remained localised in the nuclei of the embryo (Figure 4.2 C and D). The 
first signs of arrangement of the SC35 in speckles is seen in the mid 2-cell stage 
(Figure 4.2 D). An increase in the concentration of SC35 both in the nuclei (165% 
increase, n=6) and the cytoplasm (-400% increase, n=6) is seen in the late 2-cell 
embryo  (Figure  4.2  E),  compared to  the mid  2-cell  stage  (Figure  4.2  D).  The 
speckle size at the late 2-cell stage is  1.45±0.2pm.  Finally, in 4-cell and  8-cell 
stage embryos the appearance of SC35 localisation resembles that of the late 2- 
cell stage. (Figure 4.2 F and G respectively).
93Figure  4.2.  The  localisation  of SC35  during  early  embryo  development.  In  all  images  i 
corresponds to magnified image of the nucleus.  A. In pronucleus stage embryo (26h post 
hCG), SC35 is distributed uniformly in the cytoplasm. B. In late pronucleus stage embryos 
(30h post hCG), SC35 is localises the pronuclei, without any speckles being formed. SC35 
localises in the nuclei of the early embryos thereafter, in early 2-cell embryo (36h post hCG) 
(C), mid 2-cell embryo (48h post hCG) (D),  late 2-cell embryo (60h post hCG) (E),  4-cell 
embryo (F) and 8-cell embryo (G). Speckles of SC35 are seen after the late 2-cell stage.4.5
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Figure  4.3.  SC35  distribution  during  early  embryo  development.  The  ratio  of 
nuclear/cytoplasmic SC35 intensity is shown in the graph. SC35 is recruited to the nucleus 
after the late pronucleus stage.
954.2.3  PIP2 localisation during early development
To  determine  the  localisation  of nuclear  PIP2  during  early  development  and 
investigate  whether  SC35  and  PIP2  co-localise  in  early  mouse  embryos,  we 
stained oocytes and embryos using immunofluorescence with the 2C11  antibody, 
previously  characterised  by  Osborne  and  colleagues.  The  localisation  of PIP2 
varies  throughout  development.  Cumulus-enclosed  GV-stage  oocytes  show  a 
uniform  localisation  of  PIP2  within  the  GV  (Figure  4.4  A).  In  contrast,  in 
cumulus-free GV-stage oocytes there is a speckled appearance in the GV, with 
speckles of 2.15±0.5pm (n=6) (Figure 4.4 B). After GVBD, the nuclear speckles 
disappear (Figure 4.4 C).  The  staining in Mil  stage oocytes  is  identical to the 
staining shown after GVBD (Figure 4.4 D). At the pronucleus stage there is a low 
level of PIP2 in the pronuclei, which is uniformly distributed with no evidence of 
speckles (Figure 4.4 E). At the late two-cell stage the concentration of PIP2 in the 
nucleus  is  similar  to  that  seen  in  the  pronucleus  stage,  with  no  evidence  of 
speckles (Figure 4.4 F).  Some PIP2 immunofluorescence is also observed in the 
apical plasma membrane. As development of the embryos progresses through the 
4-  and  8-cell  stage,  the  level  of PIP2  immunoreactivity  in the nuclei  increases 
(Figure  4.4  G  and  H).  The  appearance  of speckles  is  shown  in  4  and  8-cell 
embryos  with  speckle  size  of  1.25±0.2pm  (n=6)  and  1.4±0.25pm  (n=6) 
respectively. In control GV-stage oocytes (Figure 4.4 I), there was no staining in 
the nucleus or the cytoplasm. In order to determine whether PIP2 and SC35 co- 
localise in early development, an attempt was made to perform co localisation
96Figure 4.4. The localisation of PIP2 during early mouse development. In all  images i 
corresponds  to  magnified  image  of  the  nucleus.  In  GV  oocytes  (A)  enclosed  in 
cumulus  cells  when  released  from  the  follicle,  PIP2  is  distributed  uniformly  in  the 
nucleus  of the  cell.  In  contrast,  GV  oocytes,  that  were  free  of cumulus  cells  upon 
release from the follicle, PIP2 appears in a speckled pattern within the GV (B). After 
GVBD  (C)  and  in  Mil  stage  oocytes  (D)  nuclear  speckles  disappear.  From  the 
pronucleus stage  (E) onwards PIP2 localises in the nuclei of the embryo, in late 2-cell 
embryos (F), 4-cell embryos (G) and 8-cell embryos (H). The first speckles appear at 
the 4-cell stage in contrast to the SC35 speckles that appear in the late 2-cell stage. I. A 
control oocyte, stained only with the secondary fluorescent antibody.experiments  using  Cy3  labelled  2C11  and  the  SC35.  Unfortunately,  the  Cy3- 
labelled  2C11  antibody failed to provide consistent results and no labelling was 
detectable, despite several attempts.
4.2.4  Speckles are not essential for normal splicing activity
The absence of SC35 and PIP2 containing nuclear speckles at the one-cell stage 
provides  an  experimental  model  to  test  whether  splicing  activity  is  present  in 
nuclei with no obvious nuclear speckles. To determine whether splicing is taking 
place in such embryos the TN24 probe was injected into the male pronucleus of 
early embryos (26h post hCG). Splicing activity was recorded in 1-cell embryos, 8 
hours  after  injection  of the  probe.  The  data  show  that  splicing  efficiency  is 
comparable to that seen in 2-cell stage embryos (Figure 4.5).
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Figure 4.5. Splicing activity of pronucleus stage embryos. Pronucleus stage embryos 
were injected with the TN24 probe 26 hours post hCG and were cultured  for 8 hours 
Pronucleus stage embryos are splicing normally despite the fact that there are no 
apparent speckles seen of either SC35 or PIP2 in the immunofluorescence data.
994.3  Conclusions
SC35  is  a  ubiquitous  SR  protein  that  plays  an  important  role  in  splicing  by 
mediating spliceosome assembly and selection of splice sites. In mouse oocytes 
and  embryos  we  find  dramatic  differences  in  the  nuclear  and  cytoplasmic 
organisation of SC35. In GV-stage oocytes the organisation of SC35 is dependant 
on the stage of oocyte development, the presence or absence of cumulus cells at 
the time of oocyte recovery and on the time after release from the follicle.
In growing oocytes the  SC35  was distributed in a reticular pattern with 
numerous  small  foci  of fluorescence.  In  fully  grown  cumulus-intact  GV-stage 
oocytes nuclear speckles had increased in size and could be identified as discrete 
units.  In  cumulus-free  oocytes  the  speckles  were  larger than  those  present  in 
cumulus-intact oocytes.  The  speckles increased further in oocytes cultured one 
hour after collection. The change in speckle organisation in maturing oocytes was 
not  affected  by  the  presence  of IBMX  to  inhibit  GVBD.  This  indicates  that 
nuclear reorganisation progresses independently of cell-cycle, at least up to the 
point at which IBMX inhibits meiotic progression.
This change in the nuclear distribution of SC35 may be explained by the 
transcriptional  state  of the  oocyte.  Growing  oocyte are highly transcriptionally 
active and this stops around the time the oocyte reaches full size (Zuccotti et al., 
1995;Bouniol-Baly et al.,  1999).  This co-insides with the time the speckles are 
increasing in size. One hour after release from the follicle, when transcription has 
ceased, the  speckles have  coalesced into  a smaller number of larger foci.  The
100difference  between  cumulus-free  and  cumulus-intact  oocyte  may  also  reflect 
transcriptional state. Cumulus-intact GV-stage oocytes are thought to arise from 
healthy  developing  follicles  in  which  normal  cumulus-cell  interactions  are  in 
place. In contrast, cumulus-free oocytes are assumed to arise from antral follicles 
in  which  the  cumulus-oocyte  junctions  have  broken  down.  In  such  oocytes, 
transcription has probably been inhibited, due to abnormal development.
It would be interesting in future experiments to correlate more directly the 
morphology of the nuclear speckles with the transcriptional state of the oocyte. In 
somatic  cells,  treatment  with  a-amanitin  to  inhibit  transcription  triggers  the 
formation of few large “speckles” (Bregman et al.,  1995). It is thought that such 
speckles  act  as  storage  units  for  the  mRNA  processing  machinery.  As 
transcription  in  initiated  the  large  aggregates  break  up  to  smaller  structures 
ultimately  to  the  size  of  spliceosomes  that  are  actively  involved  in  mRNA 
splicing.
Changes in SC35 organisation are also apparent during early development. 
In Mil oocytes, SC35 is distributed throughout the cytosol. After fertilisation, the 
Pn  accumulates  SC35,  but  in  the  early  stages  of Pn  formation,  the  ratio  of 
nuclear/cytoplasmic  SC35  is close to one.  As the cell cycle proceeds, the ratio 
increases  as  a  result  of  an  increased  nuclear  accumulation  of  SC35.  The 
explanation for this increase is not known.  It may result from the activation of 
nuclear  transport  or  as  a  result  of post-translational  modification  of SC35.  In 
nematodes there is a dephosphorylation of SR proteins during early development
101that  is  associated  with  the  increase  in  nuclear  localisation.  The  precise 
mechanism,  by  which  SC35  is  regulated  by  phosphorylation  leading  to 
accumulation of SC35 in the late  1-cell pronuclei, is not known. In-vitro studies 
show that an intermediate level of phosphorylation of SR proteins is required for 
splicing  to  take  place.  Hypo  or  hyper-phosphorylated  states  of these  proteins 
cause splicing inhibition (Cao et al., 1997;Prasad et al., 1999). In nematodes, prior 
to ZGA, it has been shown that SR proteins are in a hyperphosphorylated state 
and localise to the cytoplasm. After ZGA, partied dephosphorylation activates SR 
proteins are recruits them to the nucleus (Sanford and Bruzik,  1999;Sanford and 
Bruzik, 2001). On the other hand disassembly of the nuclear speckles has been 
shown in studies where overexpression of SR protein specific kinase 2 (SRPK2) 
increases the phosphorylation state of SR proteins (Kuroyanagi et al., 1998).
The  nuclear  accumulation  of SC35  does  not  lead  to  the  formation  of 
detectable  nuclear  speckles  at  the  1-cell  stage.  Speckles  are  evident  in  2-cell 
embryos at the stage we know splicing has been initiated. The absence of nuclear 
speckles at the one-cell stage is surprising since experiments suggest that splicing 
and mRNA processing are initiated at this stage of development (Hamatani et al., 
2004a;Zeng  and  Schultz,  2005).  We  have  tested  this  directly  by  injecting  the 
splicing reporter into 1-cell embryos. The 1-cell embryo is clearly highly capable 
of splicing mRNA, despite the apparent lack of nuclear speckles. The relationship 
of speckles between the 1-cell and 2-cell stage is not understood. It is unlikely that
102PIP2 forms a nuclear scaffold for co-ordinating this process as it coalesces into 
speckles even later that SC35.
The fact that PIP2 does not form speckles at the 2-cell stage like SC35, but 
forms speckles only later in development, suggests that it may not be involved in 
the regulation of splicing as suggested by Osbourne and colleagues. Depletion of 
PIP2 in HeLa extracts inhibited splicing activity by approximately 80%. However, 
such  depletion  probably  involved  the  depletion  of  PIP2  associated  proteins 
(possibly SC35), therefore yielding inhibition of splicing. These findings reported 
in the present study suggest that PIP2 is not involved in regulation of splicing or 
SC35  mediated  spliceosome  assembly  at  the  2-cell  stage.  More  evidence  of 
precise timing of PIP2 and SC35  co-localisation could have been achieved with 
the Cy3  labeled PIP2 antibody. Unfortunately the Cy3 labeled PIP2 antibody did 
not yield any reliable data.
The  experiments  reported  here  describe  the  developmental  changes  in 
nuclear structures associated with splicing factors such as SC35. The embryo will 
provide a useful model system in which to study the mechanism of spliceosome 
assembly and disassembly.
1035.  The role of SRp38 in early mouse 
development
5.1  Introduction
SRp38  is  a  recently  identified  protein  that  belongs  to  the  SR 
(Serine/Arginine rich) protein family. SRp38 appears in a variety of studies with a 
different name. Therefore SRp38 is also known as fusipl  (Komatsu et al., 1999), 
NSSR-1  (Komatsu  et  al.,  1999),  TASR-2  (Clinton  et  al.,  2002)  and  SRrp40 
(Cowper et al., 2001).  The structure of SRp38 is typical of an SR protein, with an 
N-terminal  RNP-type  RNA  binding  domain  and  a  C-terminal  region  rich  in 
serine-arginine dipeptide repeats (RS domain) (Shin and Manley, 2002). SRp38 is 
widely expressed. mRNA has been identified in the brain, testis (Komatsu et al., 
1999), ovary, thymus, spleen, heart skeletal muscle and placenta (Cowper et al., 
2001). In HeLa cells SRp38  localises in the nuclear speckles but shuttles to the 
cytoplasm when transcription in the cell is inhibited (Cowper et al., 2001).
The functions of SRp38 are still under investigation and have not yet been 
fully elucidated. SRp38 was first described as a regulator of splicing, when it was 
found to enhance splicing activity in vitro (Komatsu et al., 1999). Such a role has
104proved controversial and further studies have not confirmed a role in enhancing 
splicing.  SRp38 is also not sufficient to restore  splicing activity in cytoplasmic 
SI00 extracts from HeLa cells. Subsequent studies showed in SI00 extracts that 
SRp38 had a dominant negative effect on SC35 and SF2/ASF dependant splicing 
in vitro (Cowper et al, 2001;Shin and Manley, 2002). This suggested a role of 
SRp38  in splicing repression,  an unexpected property  for an  SR protein,  since 
most SR family members can activate splicing in vitro.
It was later shown that SRp38 is a potent repressor of splicing and that the 
inhibition  of  splicing  by  SRp38  is  regulated  by  phosphorylation.  In  two 
conditions,  in  which  splicing  is  inhibited,  mitosis  and  heat  shock,  SRp38  is 
activated by dephosphorylation (Shin and Manley, 2002;Shin et al, 2004). The 
phosphatase  responsible  for  dephosphorylation  of  SRp38  is  not  yet  known. 
Evidence for a role in inhibiting splicing is shown by the activation of splicing 
after  depletion  of  dephosphorylated  SRp38  (dSRp38)  and  the  inhibition  of 
splicing after addition of dSRp38 to the same extracts. The mechanism of dSRp38 
dependant inhibition appears to be due to its ability to interact with U1  snRNP 
(Shin et al, 2004) and in particular Ul-70k (Fushimi et al, 2005) and interfere 
with splice site recognition, by preventing the formation of complex A, the initial 
step  in  splicing.  Increased amounts of SC35  could not restore splicing activity 
suggesting that other SR proteins are not the target of splicing inhibition (Shin et 
al, 2004).
105An alternative mechanism has been suggested by Cowper and colleagues. 
They propose that SRp38 antagonises the activity of SR proteins such as SC35 
and SF2/ASF and inhibits splicing by exerting a dominant negative effect on their 
function. Furthermore, SRp38 activated splicing of the most distal alternative 5’ 
splice sites of adenovirus El A pre-mRNA in in vitro assays. This activity was 
shown to depend on the N-terminal RNA binding domain of SRp38 (Cowper et 
al., 2001), suggesting a further role of SRp38 in alternative splicing. Such a role 
was also shown by expression of SRp38 in NIH3T3 cells, where a decrease in a 
particular exon exclusion was demonstrated compared to control cells (Komatsu 
etal., 1999).
Recent studies have demonstrated a potential novel role of SRp38.  SRp38 
was  shown  to  regulate  neurogenesis  in  Xenopus  embryos  (Liu  and  Harland, 
2005).0verexpression  of SRp38  blocked  the  activity  of neurogenin,  a  protein 
essential  for  normal  neurogenesis,  leading  to  inhibition  of  neuronal 
differentiation. In the same study, depletion of SRp38 increased neurogenesis by 
activation of a Delta ligand, responsible for differentiation of cells into neurons in 
early  development.  There  was  no  evidence  that  this  regulation  of  neuronal 
differentiation was due to splicing inhibition or abberant splicing of a particular 
gene, such as neurogenin. The mechanism of inhibition is thought to be mediated 
by an SRp38 interaction with the 28S  rRNA. This might have an effect in the 
regulation of ribosome biosynthesis or function (Liu and Harland, 2005).
106In  this  chapter  I  have  investigated  the  role  of the  SRp38  during  early 
mouse  development.  Initial  experiments  present the  localisation  of the  protein 
during  early  mouse  development.  Further  experiments  demonstrate  that 
overexpression or depletion of the protein caused the arrest of the oocyte or the 
embryo, without any affect in the splicing efficiency of the cell when assayed with 
the TN24 probe.
1075.2  Results
5.2.1  Characterisation of the SRp38 antibody.
We firstly wanted to identify whether SRp38 is present in mouse embryos and 
whether we could see the same pattern of cell-cycle dependent dephosphorylation 
in mouse embryos. The SRp38 antibody was developed by Cocalco biological and 
was provided by James Manley as a gift. Control embryos were collected at the 
52h  post  hCG  (mid  2-cell  stage).  To  obtain  embryos  arrested  in  mitosis, 
nocodazole  was  included  in  the  culture medium to  induce  an  M-phase  arrest. 
Culture of embryos in nocodazole for 12 hours resulted in a population of mitotic 
2-cell  embryos  as  evidenced  by  the  absence  of nuclei.  Western  blotting  was 
performed on proteins from control and mitotic 2-cell embryos. The blots revealed 
two bands of the same molecular weights in the samples. One band appears to be 
of size ~35kDa and correlates with the full  length SRp38  which is 262  amino 
acids (Shin and Manley, 2002). Previous data reports that SRp38 in mouse brain, 
testis and spinal cord runs in the region of 35kDa rather than 38kDa (Komatsu et 
al., 1999;Liu et al, 2003). The second band ran at ~21kDa and correlates with the 
truncated  form  of SRp38,  which  is  183  amino  acids  (Komatsu  et  al.,  1999). 
However,  there  is  no  apparent  band  in  the  region  of  ~28kDa  where  the 
dephosphorylated form of SRp38 has been previously reported to run (Shin and 
Manley, 2004). The phosphorylation state of SRp38 could also be confirmed by 
treatment  of  control  cells  with  phosphatase  and  running  them  on  the  same 
Western  blot.  It  can  therefore  be  argued  that  the  first  band  represents  the 
phosphorylated form of SRp38. This suggests that in mouse embryos, SRp38 is in
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Figure 5.1  SRp38 runs at the same molecular weight in interphase and mitosis 
(nocodazol) in mouse embryos. The band ~35kDa represents the full length SRp38 
and the ~21kDa represents the truncated form of SRp38 known as SRp38-2. The 
fact that the protein levels between controls and nocodazol treated embryos are the 
same show that there  is no cell-cycle dependant change  in the phosphorylation 
state of SRp38.
109its  phosphorylated  state.  The  lack  of  any  shift  in  molecular  weight  in  the 
nocodazole arrested mitotic embryos suggests that there is no cell cycle-dependant 
change in the phosphorylation of SRp38 in mouse embryos (Figure 5.1).
5.2.2  SRp38 localisation during early development using immunofluorescence
Following the confirmation that SRp38 is expressed in mouse embryos, the next 
step  was  to  investigate  its  localisation using  immunofluorescence.  SRp38  was 
found  to  localise  mainly in the nucleus of the  oocyte  or embryo.  Figure  5.2A 
shows the localisation of SRp38 during oocyte maturation.  In the GV-stage the 
protein was uniformly distributed in the nucleus in the pattern of small speckles. 
After  GVBD  the  protein  was  distributed  uniformly  throughout  the  cytoplasm, 
with an accumulation of immunoreactivity on the spindle during MI.  A similar 
cytoplasmic immunofluorescence was seen at Mil, although no immunoreactivity 
was evident on the spindle.  In control GV-stage oocytes, there was no staining 
seen in the nucleus or cytoplasm. Following fertilisation, SRp38 was recruited to 
the two pronuclei of the embryo with a pattern similar to that seen in GV-stage 
oocytes (Figure 5.2B). After NEBD, the protein was distributed throughout the 
cytoplasm with an accumulation of the protein on the developing spindle. From 
the two-cell stage onwards the protein localised in the nucleus, but the appearance 
of its distribution was uniform with speckles appearing as the embryo developed 
to the late 2-cell stage (Figure 5.2B).
1105.2 A
GV
GV+ 1h
GV + 3h
M il
Control
1115.2 B
Pronucleus
NEBD
Mid 2-cell
(48h post hCG)
Late 2-cell
(60h post hCG)
4-cell
1125.2.3  The distribution and effect of SRp38-EGFP in one and 2-cell embryos
The immunofluorescence experiments and Western blot experiments showed that 
SRp38  is  expressed  in  early  mouse  oocytes  and  embryos.  To  monitor  the 
localisation of SRp38 in live cells and to determine the effect of overexpression in 
early development, an SRp38-EGFP vector was constructed by cloning the SRp38 
gene  into  pEGFP-Nl  (Clontech).  mRNA  was  prepared  using  the  vector  as  a 
template,  PCR  amplification  of  SRp38-EGFP  and  in  vitro  transcription  and 
polyadenylation (as described previously).
To  determine  the  localisation  of SRp38  in  1-cell  and  2-cell  embryos, 
mRNA  was  microinjected  to  pronucleus-stage  embryos  (26h  post  hCG).  The 
fusion protein was expressed and found to be localised in the pronuclei within 3 
hours of microinjection.  (Figure  5.3  i,  ii).  After NEBD,  SRp38  was uniformly 
distributed in the cytoplasm of the embryo (iii, iv). In mid 2-cell embryos (-48 
hours post hCG), SRp38 localised in the nuclei of the embryo (v, vi). The pattern 
of  localisation  was  the  same  as  that  demonstrated  earlier  with 
immunofluorescence. The only difference in localisation is seen after NEBD in 
the immunofluorescence experiments where there is some SRp38 localising in the 
spindle. This data confirms the nuclear localisation but not the spindle localisation 
obtained by immunofluorescence. Furthermore the data shows that the EGFP does 
not inhibit the localisation of SRp38 and suggests that SRp38-EGFP has similar 
properties as SRp38.
113Figure  5.3.  Expression  of SRp38-EGFP  after mRNA  injection  at the 
pronucleus stage.  SRp38  localises  in the pronuclei (i,  ii). After NEBD 
(iii, iv) the protein is uniformly distributed in the cytoplasm of the 1-cell 
embryo. After cleavage to the 2-cell stage, the SRp38-EGFP once again 
localised to the nuclei (v, vi).n
% of embryos developing after SRp38 over­
expression
Pronucleus NEBD 2-cell 4-cell
Control 52 0 0 6 94
SRp38-
Injected 46 0 0 100 0
Table  5.1.  Over-expression  of  SRp38  after  mRNA  injection  at  the 
pronucleus  stage  inhibits  early  development.  SRp38  overexpressing 
oocytes arrest at the 2-cell stage. Control EGFP mRNA injected embryos 
progress normally to the 4-cell stage.
115Overexpression studies are also important to determine the effects of the protein 
in  normal  development.  All  1-cell  embryos  expressing  the  SRp38-EGFP 
progressed normally to the 2-cell stage, but they did not progress any further. This 
inhibition was not due to the EGFP since the majority of control embryos injected 
with mRNA encoding EGFP progressed normally to the 4-cell stage. This result 
suggests that  SRp38  inhibits  development  beyond the  2-cell  stage,  but further 
experiments are necessary to determine whether the effect is not due to different 
concentrations of SRp38 at 1  and 2-cell stages (see below) (Table 5.1).
5.2.4  The effects of SRp38 on development and splicing efficiency
To  examine  the  effects  of  SRp38  on  2-cell  stage  development  and  splicing 
efficiency,  SRp38-EGFP  plasmid  DNA  was  injected  into  the  nuclei  of single 
blastomeres of 2-cell embryos, 42 hours post hCG. The embryos were monitored 
at ~58 hours (Figure 5.4 A), and showed that the SRp38-EGFP localised in the 
nucleus of the expressing blastomere with the appearance of some speckles seen 
at higher magnification (Figure 5.4 A iii, iv).
To determine whether this modified injection regime had a similar effect 
on development, the SRp38-EGFP-injected embryos were cultured overnight for 
16-18 hours.  Following culture, the injected blastomere with SRp38-EGFP was 
arrested, whereas the sister blastomere had divided normally, resulting in a 3-cell 
embryo (Figure 5.4 B). To ensure that the EGFP had no effect on the development 
of embryos, pEGFP-Nl  was injected into the nucleus of a single blastomere of a
1162-cell embryo. As seen in Figure 5.4C the 2-cell embryo has developed normally 
to the 8-cell stage, with the EGFP apparent both in the cytoplasm and the nuclei of 
the embryos. All  SRp38-EGFP injected blastomeres failed to cleave (n=24), as 
previously  reported,  whereas  -80%  of  blastomeres  expressing  EGFP  alone, 
progressed normally to the 4-cell stage (n=14) (Figure 5.4D).
We then tested whether the ability of SRp38-EGFP to inhibit development 
was correlated with an inhibition of splicing. This experiment was also useful to 
assess  whether  SRp38-EGFP  interfered  with  the  onset  of  EGA.  The  same 
procedure  described  above  was  performed  to  over-express  SRp38  in  2-cell 
embryos. To examine the effect of SRp38 overexpression on splicing, the TN24 
probe  was  microinjected  into  a  blastomere  of a  2-cell  embryo  overexpressing 
SRp38.  The embryos were cultured and monitored for fluorescence 8 hours after 
injection of the  splicing reporter.  To ensure that the green fluorescence  of the 
SRp38-EGFP did not interfere with the EGFP expressed from the splicing probe, 
fluorescence was collected from a region of interest that excluded the nucleus. 
This avoided contamination of the probe signal by the nuclear localised SRp38 
and  allowed  the  estimation  of  splicing  activity  as  described  in  the  previous 
chapter.  In both Figures  5.2A and 5.3A,  it is clear that SRp38  localised in the 
nucleus of the early embryos, with no detectable fluorescence in the cytoplasm. 
Furthermore, if there was some EGFP in the cytoplasm due to SRp38-EGFP, the 
low red fluorescence values of the probes
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Figure  5.4.  Overexpression  of  SRp38  in  late  2-cell  embryos  and  effect  of 
overexpression on splicing efficiency. A. SRp38-EGFP localises in the nucleus of the 
embryo  (i,  ii).  Some  aggregates  of fluorescence  (speckles)  can  be  seen  at  higher 
magnification  (iii,  iv)  (shown  by  arrowhead).  B.  SRp38-EGFP  injection  into  2-cell 
embryos  causes  developmental  arrest  in  the  injected  blastomere  (i,  ii).  Bright  field 
image shows a 3-cell embryo and fluorescence image shows SRp38-EGFP localised to 
the nucleus of the injected blastomere. The control blastomere has divided normally. C. 
Injection  of pEGFP-Nl  has  no  effect on  development of injected  blastomeres  (80% 
cleave). This confirms that injection technique and EGFP do not cause cleavage arrest 
and developmental effects are a result of SRp38.. Overexpression of SRp38 in late 2-cell 
embryos and effect of overexpression on splicing efficiency. D. Data showing rates of 
development to the 4-cell stage (n=24). Note that none of the SRp38-EGFP-injected 
blastomeres  cleave to allow development to the 4-cell stage, while 80% of the control 
blastomeres  cleave.  E.  Overexpression of SRp38  does not affect splicing  efficiency. 
Overexpressing SRp38 embryos were injected with the TN24 probe at the mid 2-cell 
stage. Each point on the graph represents a blastomere of a 2-cell embryo at the late 2- 
cell stage.
119would appear with a much higher green fluorescence than expected.  However, 
such a result was not obtained. In the Figure 5.4E, the red fluorescence reflects 
transcriptional activity of the probe whereas green fluorescence reflects splicing 
activity. The green fluorescence intensity for a given transcription level is shown 
to be similar in controls and embryos overexpressing SRp38. This suggests that 
there  is  no  significant  difference  in  the  splicing  efficiency  between  embryos 
overexpressing  SRp38  and  control  embryos.  Furthermore,  the  fact  that  the 
transcriptional level (red fluorescence) is not affected in overexpressing embryos 
is strong evidence that SRp38 does not interfere with the onset of transcription at 
the 2-cell stage.
5.2.5  Effect of SRp38 depletion on development and splicing efficiency
To  investigate  whether  the  endogenous  SRp38  protein  is  important  for 
development and splicing we have used a morpholino approach in an effort to 
deplete the SRp38 protein from 2-cell embryos. To allow a maximum opportunity 
for endogenous SRp38 to turnover, the morpholinos were injected at the one cell 
stage. To confirm that the morpholino injection resulted in depletion of the SRp38 
protein,  embryos  were  microinjected  with  an  SRp38  morpholino  or  a  control 
scrambled  morpholino.  The  levels  of  SRp38  were  examined  using 
immunofluorescence  and  Metamorph  analysis  (Figure  5.5 A).
Immunofluorescence revealed that SRp38 was reduced to -30% of that seen in 
control embryos when nucleus/cytoplasm pixel intensities were compared (Figure
120B Effect of Morpholino on SRp38 levels in 2-cell 
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Figure 5.5. SRp38 morpholino decreases the level of SRp38 immunoreactivity. 
A i to A iv show immunofluorescence and bright field images of control (i, ii) 
and  morpholino-  injected  (iii,  iv)  2-cell  embryos.  B.  Graph  shows  the 
difference in fluorescence between control and morpholino injected embryos.5.5B).  A  western  blot  of control  and  morpholino-injected  embryos  showed  a 
reduction in the level of SRp38 protein in the morpholino-injected embryos. The 
blots were re-probed for actin to confirm that similar levels of protein were loaded 
in each lane. The graphs beside each band show the mean pixel intensity of each 
band.  The level of SRp38, as determined by pixel intensity, decreased by 70%. 
The level of the truncated SRp38 was reduced by 50%.  Actin was not affected by 
the treatment with the morpholino (Figure 5.6).
The effect of SRp38 depletion in development was monitored by culturing 
control and SRp38 morpholino injected embryos to the 4-cell stage. Ten percent 
of the morpholino injected embryos arrested at the 1-cell stage with the remaining 
embryos  subsequently  arresting  at  the  2-cell  stage.  Control  embryos  (95%) 
developed to the 4-cell stage when the culture was terminated (Table 5.2).
In order to determine whether the splicing efficiency of the embryos was 
affected following depletion of the SRp38, the TN24 probe was injected at the 
mid  2-cell  stage  embryos  previously  injected  with  the  SRp38  or  control 
morpholino (at pronucleus stage). Eight hours after injection of the TN24 probe, 
the splicing efficiency was examined. The data clearly show that the depletion of 
SRp38  had  no  effect  on  splicing  efficiency  of  2-cell  embryos.
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123Stage of development reached after 48 hours of culture
n Pronucleus 2-cell 4-cell
SRp38-
morpholino-
injected
108 11 % 89% 0%
Control-
morpholino-
injected
102 0% 6% 94%
Table 5.2. Effect of SRp38 morpholino on embryo development. The majority 
of control injected embryos develop normally to the 4-cell stage. However, the 
injection of the SRp38 morpholino has arrested development partially by the 
pronucleus stage and completely by the 2-cell stage.
1245.2.6  Overexpression or depletion of SRp38 also inhibits oocyte maturation
Previous results in 5.2.4 showed that there was no direct or significant effect of 
the overexpression of SRp38 on splicing efficiency. If the effect of the protein is 
independent  of splicing  it  may  also  be  expected  to  have  an  effect  on  oocyte 
maturation, since it is though to be independent of new transcription. GV-stage 
oocytes were arrested with IBMX and injected with SRp38-EGFP mRNA. After 
overnight  culture,  the  GV-stage  oocytes  were  then  released  from  IBMX  and 
cultured for 15 hours. Figure 5.7 shows a GV-stage oocyte, injected with SRp38- 
EGFP. SRp38-EGFP localised to the GV, with some evidence of speckles around 
the  nucleolus.  After  release  of  oocytes  from  IBMX,  SRp38-EGFP-injected 
oocytes  failed  to  undergo  GVBD.  Control  oocytes  and  oocyte  cultured  in  a- 
amanitin (RNA polymerase II inhibitor) underwent GVBD with 100% and 93%, 
respectively, progressing to Mil (Table 5.3).
Depletion of SRp38 from oocytes was also examined to determine whether 
oocyte maturation would be affected. The GV-stage oocytes were injected with 
the morpholino and cultured overnight in the presence of IBMX. As for 2-cell 
embryos, we confirmed that the SRp38 morpholino-injected embryos showed a 
significant decrease in protein levels to -30% of that seen in controls injected with 
a  scrambled  morpholino  (Figure  5.8A,  B).  The  majority  of control  GV-stage 
oocytes matured to Mil stage at a rate of -90%. However, -30% of morpholino
125injected GV-stage oocytes arrested at the GV stage upon release from IBMX. The 
remaining morpholino injected oocytes arrested at the MI stage (Table 5.4).
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Figure  5.7.  Expression of SRp38-EGFP  in GV oocytes.  The GV oocytes were 
injected with SRp38 mRNA and cultured overnight in IBMX enriched media. The 
GV-stage oocytes were released and cultured  for  15  hours  (i,  SRp38-EGFP,  ii, 
Hoechst staining, iii merge image of i and ii, iv, bright field image).
127Stage
n
% of oocytes
GV MI Mil
Control 105 0 0 100
a-amanitin 98 0 7 93
SRp38-
EGFP
78 100 0 0
Table 5.3. Effect of overexpression of SRp38 on oocyte maturation. Arrested GV- 
stage oocytes were injected with SRp38 mRNA and cultured overnight in presence 
of IBMX. Upon release, all SRp38-EGFP-injected GV oocytes remain arrested at 
the GV stage. Control oocytes and oocytes cultured in a-amanitin enriched media 
progress to the Mil stage upon release.
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B Effect of Morpholino on SRp38 level in GV 
oocytes
95
3   90
I 6 5  
«  80
Control Morpholino
Figure 5.8.  Effect of SRp38 morpholino on oocyte maturation.  Ai to Aiv show 
immunofluorescence images of control (i, ii)  and morpholino injected (iii, iv)  GV 
oocytes.  B.  Graph  shows  the  reduction  in  fluorescence  between  control  and 
morpholino injected GV oocytes.
129n
% of oocytes
GV Ml Mil
Control 94 0 12 88
Morpholino 90 27 73 0
Table 5.4.  Effect of morpholino on oocyte maturation.  The majority of control 
injected oocytes progress to the Mil stage. However, morpholino injected oocytes 
do not progress further than the MI stage
1305.3  Conclusions
This  chapter  presents  the  role  of  the  SR  protein  SRp38  in  early  mouse 
development.  Western blot  results  show  expression  of both  full  length  SRp38 
(~35kDa) and the truncated form of SRp38 (~20kDa) in early mouse embryos. In 
studies on mouse brain, spinal cord and testis tissues, SRp38 has been shown to 
run at a molecular weight of ~35kDa (Liu et al., 2003). This in contrast to HeLa 
cell  studies  in  which the  protein  has  been  shown  to  run  at  38kDa  (Shin  and 
Manley, 2002). The dephosphorylated form of SRp38 has been reported by Shin 
and Manley to appear in the region of 28kDa. The fact that we failed to detect a 
band in the region of ~28kDa as well as the fact that SRp38  runs at the same 
molecular  weight  in  interphase  and  mitosis  (nocodazol  treatment),  shows  that 
there is no dephosphorylated SRp38 in early mouse embryos. It is unclear why 
mouse  embryos  do not  show any dSRp38,  while evidence does exist in HeLa 
cells. It may be that the levels of dSRp38 are below the level of detection, or that 
the dSRp38 phosphatase is not expressed in the oocyte. These results suggest that 
the dephosphorylation of SRp38 may not be important in regulation of splicing 
during early mammalian development.
The protein was shown to localise by immunofluorescence or expression 
of SRp38-EGFP to the nuclei at a number of different stages; GV-stage oocyte, 1- 
cell  embryo  and  2-cell  embryo.  During  mitosis  the  protein  distributed  to  the 
cytoplasm.  Within  the  nucleus  the  protein  appears  to  concentrate  in  nuclear 
speckles.  This localisation of SRp38 in speckles was previously shown in cos7
131cells  by  Cowper  and  colleagues  (Cowper  et  al,  2001).  It  was  suggested  by 
Cowper  and  colleagues  that  the  nuclear  speckles  resemble  the  localisation  of 
SC35  speckles. No evidence was provided to show co-localisation of the SC35 
and SRp38. In the experiments presented here, speckles using the SRp38 antibody 
and the SRp38-EGFP, appear fewer in number than the speckles detected using 
SC35  (see  previous  chapter).  To  elucidate  whether  SRp38  and  SC35  are  co­
localised  further  experiments  using  fluorescent  fusion  proteins  or  dual 
immunofluorescence labelling experiments are required.
The majority of SR family proteins are known to be splicing activators or 
enhancers (Graveley, 2000). However, it has been previously demonstrated that 
SRp38  possesses  properties  of  a  splicing  repressor,  rather  than  activator  or 
enhancer,  especially  during mitosis  and  in  response to  heat  shock  (Shin  and 
Manley, 2002;Shin et al., 2004). Our findings are consistent with a role for SRp38 
on early development being independent of splicing. Depletion or overexpression 
of SRp38 inhibited development at the 2-cell stage. These effects were initially 
shown to be independent of splicing by the use of the TN24 splicing reporter. The 
TN24  probe  was  selected  due  to  the  fact  that  it  presented  a  greater  splicing 
efficiency compared to the other introns. In both cases, neither a decrease nor an 
increase in the splicing efficiency was observed when the TN24 probe was used. 
This  finding  may  be  explained  in  part  by  the  finding  that  embryos  do  not 
apparently contain any dephosphorylated SRp38, which has been shown to be the 
most potent  form  of SRp38  for inhibiting  splicing activity  (Shin and  Manley,
1322002). An alternative explanation for not detecting any change in splicing activity 
may be that the TN24 splicing probe is not targeted or not sensitive enough to 
detect effects of SRp38 on splicing. For example TN24 will not report alternative 
splicing activity and previous studies have suggested that SRp38 is involved in 
splice  site  selection  (Komatsu  et  al.,  1999;Cowper  et  al.,  2001;Nasim  et  al., 
2002). SRp38 has been shown to exert dominant negative effects on the activity of 
other  splicing  activators  or  enhancers  (Cowper  et al,  2001;Shin  and Manley, 
2002). As such, the overexpression of SRp38 may interfere with the balance of 
activity of these splicing activators or enhancers, leading to aberrant alternative 
splicing.  This  may  be  one  possible  mechanism  of action  responsible  for  the 
developmental arrest caused by modulating levels of SRp38.
The  depletion  or  overexpression  experiments  performed  on  GV-stage 
oocytes  argue  that  the  developmental  effects  are  independent  of splicing  and 
alternative  splicing.  GV-stage  oocytes  do  not  transcribe  and therefore  are  not 
actively splicing mRNA. This is illustrated by the experiment with a-amanitin, an 
RNA Polymerase II inhibitor, where the GV-stage oocytes matured normally to 
the Mil stage.  It would be interesting at this stage to find out whether splicing 
efficiency  was  affected  in  GV-stage  oocytes  expressing  high  or  low  levels of 
SRp38. This would require oocytes that are not transcriptionally active to retain 
the capacity to splice mRNA. There is one example, were this has been shown to 
occur in platelets (Denis et al., 2005). Unfortunately, the TN24 reporter cannot be 
used at this stage to monitor splicing efficiency, as it requires transcription to be
133taking place. The fact that overexpression or depletion of SRp38 from GV-stage 
oocytes leads to arrest prior to GVBD, suggests an involvement of SRp38 with a 
cell cycle mechanism or another house-keeping process other than splicing. The 
only stage that was insensitive to different levels of SRp38 was the pronucleate 
stage, where excess of SRp38 had no effect on development to the 2-cell stage.
The fact that the effects on development are apparently independent of 
splicing raises the question of how development is affected when SRp38 levels 
are  modulated.  SRp38  overexpression  or  depletion  was  recently  shown  to 
interfere with normal neuronal differentiation, an effect independent of splicing 
(Liu  and  Harland,  2005).  Overexpression  of SRp38  blocked  the  activity  of a 
protein essential for normal neurogenesis, whereas depletion of SRp38 increased 
neurogenesis by activation of a pathway responsible for differentiation of cells 
into neurons in early development. A possible explanation could be that SRp38 
regulates  a  currently  unknown  pathway  in  oocytes  or  early  embryos  that  is 
independent of splicing.  The pathways  of transcription,  translation and  protein 
synthesis  however  can  be  excluded  because  they  were  not  affected  in  our 
experiments.
The  depletion  of other  SR  proteins  from  early  embryos  also  inhibits 
normal development. When the SR protein SRp20 gene was inactivated by Cre- 
loxP  mediated  recombination,  the  embryos  failed  to  develop  to  the  blastocyst 
stage  and  died  at  the  morula  stage  (Jumaa  et  al.,  1999).  Another  study  in 
Drosophila showed that normal development was inhibited when a null mutant of
134the SR protein SRp55 was generated. The development was inhibited in the first 
and second-instar larval  stages.  It was also  shown in the  same  study that both 
constitutive  and  alternative  splicing  of  endogenous  genes  were  unaffected, 
suggesting that the SR protein is not essential  for all splicing  and is possibly 
involved in other functions (Ring and Lis, 1994).
As mentioned in the introduction, novel roles for SR proteins have been 
proposed.  It may be that these  SR proteins  are  essential  in  early development 
because  they  are  required  in  mRNA  export,  translation,  surveillance,  or other 
processes not yet described.
1356. Discussion
The aim of this work was to develop a splicing assay that would work on single 
living  cells  and  to  investigate  the  role  and  regulation  of  splicing  in  early 
mammalian embryos. The splicing machinery was investigated using living and 
fixed mouse oocytes and embryos by the use of GFP fusion proteins and imaging 
techniques, combined with techniques for manipulating the levels of the proteins 
of interest.
For many years splicing activity has been studied using splicing assays 
that use a particular mRNA transcript, mainly the beta-globin gene. The in vitro 
prepared transcript is introduced in cell extracts that splice the mRNA and the 
splicing efficiency is determined by running the mRNA products on a gel and 
measuring  relative  levels  of spliced  and  unspliced  products.  Such  techniques 
would not be possible in experiments involving early embryos, because of the 
requirement of large numbers of cells for preparing the cell extracts, equivalent to 
approximately one thousand embryos. The development of our novel fluorescent 
probe  enabled  us  to  measure  splicing  efficiency  in  single  cells  of  early 
mammalian embryos. Two fluorescent proteins DsRed Express and EGFP were 
intervened by an intronic sequence that included stop codons. Upon injection of 
the intact vector DNA into single blastomeres of early mouse embryos, the two 
proteins  were  expressed.  Splicing  would  excise the  intron containing the  stop
136codons and would yield the DsRed Express-EGFP fusion protein. In the absence 
of splicing, only the DsRed Express would be present. Fluorescence from DsRed 
Express  therefore  reflects the  transcriptional  activity  of the  embryos,  whereas 
green fluorescence reflects splicing activity. This technique proved to yield rapid 
results determined by the time taken to express the reporter. Analysis of splicing 
using this technique requires straight forward image analysis and there is no need 
for  laborious  biochemical  protocols.  The  properties  of the  probe  were  tested 
against a number of conditions including the deletion of the 5’ splice site, the use 
of different introns and the inhibition of Ul. In all cases the data were consistent 
with the conclusion that the probe was a reliable reporter of splicing activity.
In the lead up to developing this splicing reporter we underwent a number 
of iterations before finally obtaining a combination of fluorescent proteins that 
behaved reliably. For purposes of clarity, these preparatory steps have not been 
presented in this thesis. Nevertheless, it is valuable to comment on the properties 
that maximise the chance of success when developing such fluorescent probes. 
EGFP  is  an  obvious  choice  due  to  its  high  efficiency  and  extensive 
characterisation.  A  number  of different  partners  were  considered.  CFP  was  a 
possibility, but its relative low fluorescence and the requirement for excitation at 
shorter wavelengths raised some concerns about long term experiments. On the 
other hand red fluorescent proteins allow the experimenter to  avoid the use of 
short  wavelength  excitation  while  maintaining  similar  fluorescent  spectra  that 
allows it to be separated from EGFP (Clontech UK).
137Initial attempts to develop the probe with an RFP proved problematic. At 
the time of these initial experiments the best RFP available was DsRed2, rather 
than DsRed Express. DsRed2 proved to be entirely unsuitable for the purposes of 
the splicing probe. Firstly, the time of maturation of the red fluorophore exceeded 
15  hours,  allowing  the  embryos  to  progress  to  the  4-cell  stage,  prior  to  the 
detection  of  any  red  fluorescence.  Secondly,  DsRed2  initially  emits  green 
fluorescence and only upon maturation does it yield red fluorescence. For these 
two reasons DsRed Express was, fortunately for this study, marketed by Clontech 
and was used to construct new vectors which proved ideal for the purpose of this 
study.  DsRed Express does not fluoresce at all in the  green spectrum and can 
mature and fold to obtain maximum fluorescence within 3 hours. These properties 
make it an ideal partner for EGFP. It was also important for the success of the 
probe that the two proteins had similar properties so that data for transcription 
(RFP) and splicing (EGFP) are obtained with similar kinetics.
DsRed Express as well as EGFP proteins mutated in many sites compared 
to  their  wild  type  counterparts  form  in  order  to  yield  faster  maturation  time, 
greater stability and solubility and reduced aggregation. DsRed 1  and 2 are known 
to form tetramers and in the longer term to form aggregates. These aggregates are 
not  desired  for  reasons  of  toxicity  and  also  because  they  complicate  the 
fluorescent readings. Mutations inserted in DsRed Express significantly reduced 
the formation of such aggregates. During our experiments we could only see the 
formation  of  small  aggregates  at  extremely  high  concentrations  of  red
138fluorescence, i.e. over 4000 AUs. Therefore no experiments were performed at a 
concentration of red fluorescence over 2500-3000 AUs. A potential solution for 
solving such a problem would be the substitution of DsRed Express with DsRed 
Monomer,  a protein  recently  presented  by  Clontech.  This  protein  contains  45 
amino acids substitutions so that it does not form any tetramers while maintaining 
similar spectral and maturation properties of DsRed Express. Even though DsRed 
Monomer would be a better candidate for such a probe it would not be advisable 
to perform experiments at such high concentrations, because we have proposed 
that the divergence in the rate of transcription and splicing seen in our studies may 
be due to saturation of splicing machinery.
We could demonstrate that splicing could also  be performed efficiently 
when a number of introns were used in the probe. This allows for the substitution 
of the existing intron with alternative introns to allow splicing efficiency to be 
measured  in  single  cells  in  systems  where  the  intron  consensus  or  splicing 
enhancer / silencer are important. Furthermore, the incorporation of cryptic splice 
sites within the fluorescent proteins may provide additional tools for monitoring 
splicing.  These vectors could be designed in such a way that upon splicing of 
cryptic splice site, the fluorescence of the protein with the cryptic splice site is 
eliminated.  Therefore,  such  probes  would  be  important  in  studies  where 
alternative splicing is important.
Another possibility would be to design probes that would be specific for 
measuring splicing activity in the presence of enhancer sequences.  Our Ml M2
139probe and M1M2AE probes were a good starting point but there is no splice site 
competition  in these  probes.  Therefore,  the  results  may  not  reflect the  splicing 
events occurring in a dynamic system. A suggestion of the some new probes that 
would allow monitoring of enhancer sequences is shown in the figure below.
Exon EGFP
Probe 1
Probe 2
RFP Exon EGFP
RFP Exon EGFP
Other splicing 
events
Exon
Exon including 
enhancer sequence
RFP
Figure 6.1. A schematic of the two probes that allow the monitoring of splicing when an 
enhancer sequence  is  used  in an exon  flanked  by  splice  site that would  intervene the 
current intron sequence. The three possible splicing events are shown with numbers. The 
outcomes  of expression  depending  to  the  splicing  events  in  the  two  probes  are  also 
shown.
A  vector  could  be  constructed  as  presented  above  in  figure  6.1.  The 
existing single intron of our current probe (e.g. TN24) could be intervened by an 
exon flanked by splice  sites that contains the enhancer sequence.  This set up of
140the  probe  would  introduce  splice  site  competition.  There  are  three  potential 
splicing  events  that  could  occur  shown  in  the  figure  with  the  corresponding 
number.  To  investigate  whether  splicing  event  one  has  taken  place  (event 
enhanced by the enhancer sequence), over the other splicing events, the construct 
would be designed in such a way that EGFP is expressed only if splicing event 
one is taking place. All other splicing events would only yield RFP. This probe 
however, would not distinguish as to whether splicing event 2 or splicing event 3 
was the reason for expression of the RFP on its own. This can be achieved by 
designing EGFP to be out of frame in these two cases. To resolve this problem a 
second  probe  could  be  designed  in  such  a  way  that  splicing  events  1  and  2 
occurring together would express the EGFP. Any other combination in splicing 
events would yield RFP on its own. Combining the data from the 2 probes, would 
allow  the  determination  of which  splicing  event  and  to  what  extent  splicing 
activity was influenced by the enhancer sequence.
The  integration  of  a  splicing  probe  within  cell  lines  would  also  be 
beneficial.  Cell  lines  that  stably  express  a  splicing  probe  would  not  require 
transfection and therefore could be used for screening of drugs or screening of 
libraries to monitor splicing activity. Some preliminary experiments performed at 
Ian Eperon’s  laboratory at University of Leicester show that the expression of 
such an integrated probe in cell lines occurs within 12-18h, which is a short period 
of  time  compared  to  the  72h  incubation  periods  essential  after  transient- 
transfection experiments.
141Fluorescent  proteins  have  not  normally  been  used  in  splicing  assays, 
however, they have been shown to be very powerful tools for localisation studies. 
In this work we have used an SRp38-EGFP fusion protein to address a number of 
questions. Firstly, to monitor the localisation of the protein during development 
and  secondly  to  investigate  its  effect  on  development  and  splicing  of early 
embryos. Unlike immunofluorescence, the use of the GFP-tagged proteins allows 
the monitoring of the protein in single living oocytes and embryos. This provides 
a means of studying dynamic events in relation to the developmental processes 
that  the  proteins  under  examination  may  be  involved.  In  addition,  possible 
artefacts  produced  by  the  fixing  process  during  immunofluorescence  can  be 
avoided by the use of GFP technology.
In order to investigate SRp38 in live cells, SRp38 was cloned into pEGFP- 
Nl.  The  N-terminal  of the  SRp38  is  involved  in  RNA  binding  interactions, 
whereas the C-terminal of SRp38 possesses the RS domain involved in protein- 
protein interactions. Therefore, EGFP is expressed downstream of SRp38’s RS 
domain.  EGFP  fusion  proteins  have  been  successfully  used  for monitoring  of 
protein  function  and  localisation  experiments,  without  interfering  with  the 
protein’s properties.  Nevertheless,  it could be argued that EGFP  may  interfere 
with  the  RS  domain  of SRp38.  Our  immunofluorescence  data  correlates  very 
closely  with  the  localisation  data  obtained  by  the  SRp38-EGFP  protein.  The 
immunofluorescence data therefore could confirm that the distribution of SRp38- 
EGFP was not affected by the EGFP tag.  The effects of the overexpression of
142SRp38 were quite surprising. SRp38 has been characterised as a potent inhibitor 
of splicing especially in its dephosphorylated form (Shin and Manley, 2002). The 
phosphorylated form of the protein should also inhibit splicing to a less extent 
(Shin  and  Manley,  2002).  However,  we  could  not  show  with  our  probe  that 
splicing  was  inhibited  in  early  embryos.  The  fact  that  overexpression  of the 
protein  inhibited  the  development  of GV-stage  oocytes  (a  stage  in  which  no 
transcription is taking place), as well as previous data of dysregulation of neuronal 
differentiation (Liu and Harland, 2005), suggest that the protein may be involved 
in processes other than splicing.  This finding is not surprising.  In the past,  SR 
proteins  were believed  to  be  splicing regulators.  However recent  studies  have 
implicated them in mRNA translation, mRNA export and mRNA surveillance and 
quality control. Our data suggests that SRp38 might interfere with mechanisms 
necessary  for  oocyte  maturation  and  early  embryo  development.  It  is  also 
important to mention that the use of a new fluorescent probe, such as the SRp38- 
EGFP needs extensive characterisation to ensure that the signal is a true reflection 
of the behaviour of the probe and that the fluorophore used does not interfere with 
the normal progression of the cell cycle in a non-specific way.  Comparison of 
immunofluorescence and live imaging has revealed that our SRp38-EGFP fusion 
protein presented the same pattern of localisation. The fact that EGFP expressed 
in the cell did not inhibit normal development suggests that the findings of our 
experiments reveal the effects of SRp38 rather than the effects of EGFP.
143Depletion of a protein can also yield useful information on the importance 
of such a protein during these early stages in development. There are two main 
techniques  widely  used  for  the  depletion  of  proteins.  The  method  of  RNA 
interference (RNAi) involves the injection of RNA with complementary sequence 
to the protein’s in question mRNA. Upon formation of the mRNA duplex, the 
mRNA  is  degraded resulting in  depletion  of the  protein.  A  second method of 
protein depletion involves the use of a morpholino oligo. In a similar principle as 
with  RNAi,  a  cDNA  oligonucleotide,  complementary  to  the  target  mRNA 
sequence is injected in the cell. In this case the mRNA is not degraded, but the 
morpholino molecule inhibits the binding of the translational machinery onto the 
mRNA  molecule  thus  inhibiting  its  expression.  The  use  of  the  morpholino 
approach in this study was partially successful in the case of SRp38. Depletion 
caused the arrest of the depleted embryos at the 2-cell stage. This finding was not 
surprising due to the fact that zygotic genome activation occurs at the same time 
that the protein was depleted from the cell, around the 2-cell stage.
Recent micro-array  studies have revealed that the  first genes  expressed 
during  zygotic  genome activation include transcription and  splicing  factors.  In 
particular, three  SR proteins genes,  Srfsl,  Srfs5,  Srfs7 have been identified by 
transcript profiling studies to be expressed from the late 1-cell stage (Zeng et al, 
2004;Hamatani  et  al,  2004a).  Depletion  or  overexpression  of SRp38  did  not 
inhibit splicing activity.
144In HeLa cells splicing was shown to be regulated by a nuclear PIP2 pool 
that localises with SC35. Osbourne and colleagues (2001) performed experiments 
in which splicing was  inhibited  in cell  extracts depleted of PIP2.  However the 
protocols used for the depletion of PIP2 could potentially eliminate other factors 
and one of those could be SC35 since it co-localised with PIP2. SC35 is known to 
be  a  potent  activator  of splicing,  and  its  depletion  from  the  cell  could  have 
detrimental effects to the cell splicing machinery. Our immunofluorescence data 
presents the SC35 arranging in speckles during the late 2-cell stage. However, the 
PIP2 is presented with a uniform distribution at the late 2-cell stage and arranges 
in speckles from the 4-cell stage onwards. This data therefore suggests that it is 
not nuclear PIP2 that regulates splicing in early development since its organisation 
in the speckle is later than that seen by SC35.
Splicing, as mentioned earlier, is an essential process for gene expression 
and  therefore  it is  very carefully regulated during early development.  Splicing 
stops when transcription stops when the oocytes are fully grown. In order to begin 
at the onset of transcription, maternal splicing factors must remain to perform this 
function.  It  is  not  known  whether  these  proteins  are  stored,  or  whether  new 
translation  is  necessary.  However,  recent RNA  profiling  studies  show that  SR 
proteins are expressed as early as the late 1-cell stage (Zeng et al, 2004;Hamatani 
et al., 2004a). This suggests that maternal splicing factors support splicing at this 
very early stages of development, for the expression of splicing factors required
145for development. The expression of these embryonic splicing factors may then be 
used for splicing of genes expressed from the mid-late 2-cell stage onwards.
This thesis presents a novel fluorescent reporter that allows the monitoring 
of splicing activity in early embryos. This reporter was used as a valuable tool in 
this thesis, to  investigate  splicing activity in early mammalian development.  It 
was  demonstrated that the  embryos  are  capable  to  splice  from the pronucleus 
stage, even without the appearance of spliceosomes in the nuclei. Finally, it was 
presented  the  SR protein  SRp38  plays  an  important  role  in  early  mammalian 
development, in splicing and possibly other processes.
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